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Abbreviations 
3D   three dimensional 
A2M   alpha-2-macroglobulin 
ABL   Abelson murine leukemia viral oncogene homolog 
ac   alternating current 
AGC   automatic gain control 
AKT   protein kinase B, or Rac (RAC-alpha serine/threonine-protein kinase;
   the term AKT originates from the transformed AKR mouse strain.  
ATF2   activating transcription factor 2 
ATP   adenosine triphosphate  
BCR    breakpoint cluster region protein 
CAMK  calcium/calmodulin dependent protein kinase; 
CDKs   cyclin-dependent kinases 
CID   collision induced fragmentation 
CK1   casein protein kinases 
c-Kit   proto-oncogene tyrosine-protein kinase Kit, or mast/stem cell growth 
   factor receptor  
CML   chronic myelogenous leukemia 
dc   direct current 
DHB   2,5-dihydroxy benzoic acid 
DMEs   drug metabolizing enzymes 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
ECD   electron capture dissociation 
ECM   extracellular matrix 
EDTA   ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
EMEA   European Medicines Agency 
ErbB   epidermal growth factor receptor (EGFR) family 
ERK   extracellular signal-regulated kinases 
ESI   electrospray ionization 
ETD   electro transfer dissociation 
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FDA   US Food and Drug Administration 
FDR   false discovery rate 
Flt-3   FL cytokine receptor precursor, tyrosine protein kinase receptor 
FTICR   Fourier transform ion cyclotron resonance 
GAP   GTP activated protein 
GIST   gastrointestinal stromal tumors 
GLEPP1  glomerular epithelial protein 1 or receptor-type tyrosine-protein  
   phosphatase O 
GLUT   glucose transporter 
GO   Gene Ontology 
GTP   guanosine triphosphate 
HIFs   hypoxia-induced factors 
HGF   hepatocyte growth factor 
HPLC   high performance liquid chromatography 
HSP   heat shock protein 
HSP27   heat shock protein 27 
IGF   insulin-like growth factor 
IMAC   immobilized metal ion affinity chromatography, 
IP   immunoprecipitation 
IRMPD  infrared multiphoton dissociation 
IRS2   insulin receptor substrate 2 
iTRAQ  isobaric tag for relative and absolute quantitation 
JAKs   Janus kinase, tyrosine protein kianse 
JNK   C-jun-amino-terminal kinase 
LDL   low-density lipoprotein 
LTQ   linear quadrupole ion trap 
LYN   tyrosine protein kinase LYN 
m/z   mass to charge ratio 
MALDI  matrix-assisted laser desorption/ionization 
MAP3K  mitogen-activated protein kinase kinase kinase 
MAP2K  mitogen-activated protein kinase kinase 
MAPK   mitogen-activated protein kinase 
MAPKAP kinase MAPK activated protein kinase 
MBP-C   mannose-binding protein C 
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MeCN   acetonitrile 
MEK   dual specificity mitogen-activated protein kinase kinase 
MS   mass spectrometry 
MSK2   nuclear mitogen-and stress-activated protein kinase 2 or ribosomal  
   protein S6 kinase alpha-4 
mTOR   mammalian target of rapamycin 
Myc   Myc proto-oncogene protein, transcription factor p64 
nanoESI  nanoelectrospray ionization 
NF1   neurofibromin or Neurofibromatosis-related protein NF-1 
NFκB   nuclear factor kappa B 
p90RSK  ribosomal protein S6 kinase alpha 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDGFR  platelet-derived growth factor receptor precursor 
PDK-1   phosphoinositide-dependant kinase-1 
PEP   posterior error probability 
PI3K   Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKA   protein kinase A 
PLC   phosphoinositide phospholipase C 
PP1   protein phosphatase 1, serine/threonine phosphatase 
PP2A   protein phosphatase 2A, serine/threonine phosphatase 
PP2B   serine/threonine-protein phosphatase 2B, calmodulin-dependent  
   calcineurin A 
PTEN   phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual- 
   specificity protein phosphatase 
PTKs   protein tyrosine kinases 
PTM   post translational modification 
PTPs   protein tyrosine phosphatases 
RasGAP  Ras GTPase-activating protein 
Rb   retinoblastoma 
RET   proto-oncogene tyrosine-protein kinase receptor ret precursor 
rf   radio frequency 
ROS   reactive oxygen species 
RP HPLC  reverse phase high performance liquid chromatography 
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RTKs   receptor tyrosine kinases 
SCFR   synonym of KIT 
SCX   strong cation exchange 
SDS-PAGE  isodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHIP2   phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 
SHP-1   tyrosine-protein phosphatase non-receptor type 6 
SHP-2   tyrosine-protein phosphatase non-receptor type 11 
SILAC   stable isotope labeling by amino acids in cell culture 
Smad2/3  mothers against decapentaplegic homolog 2/3 
SOP   standard operating procedures 
SORI   sustained off resonance irradiation 
Src   proto-oncogene tyrosine-protein kinase Src 
STAT   signal transducer and activator of transcription 
STE   group of homologs of yeast sterile protein kinases 
TCA   tricarboxylic acid 
TFA   trifluoroacetic acid 
TGF-β   transforming growth factor β 
TGFβ R1  transforming growth factor β type 1 receptor 
TKL   tyrosine kinase like 
TNFR   tumor-necrosis factor receptor 
TSC2   tuberous sclerosis 2 protein 
VEGFR  vascular endothelial growth factor receptor 
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Summary 
This thesis applies quantitative mass spectrometry to research topics in relation to cancer. 
Proteome-wide quantification at the protein expression level and phosphorylation level were 
achieved. The technologies developed and used here cover the latest improvements in 
instrumentation in mass spectrometry, strategies in phosphopeptide enrichment in large scale, 
algorithms in data analysis and their streamlined implementation, and data mining in 
downstream bioinformatics. For each of the projects described in this thesis, proteome 
mapping routinely resulted in identification and quantitation of around 4,000 proteins and 
phosphoproteome mapping often lead to quantitation of more than 5,000 phosphorylation sites. 
This ‘systems-wide’ quantitation of the proteome and phosphoproteome is a completely novel 
development, which has not been used in cancer related topics before.  
Three major biology topics are studied in this thesis. In the first project, the phosphoproteome 
of a mouse liver cancer cell line Hepa1-6 was analyzed in-depth, by using phosphatase 
inhibitors (calyculin A, deltamethrin, and Na-pervanadate) to boost phosphorylation. The 
characterization of the phosphoproteome revealed a broad spectrum of cellular 
compartmentalization and biological functions. Quantitation of phosphatase inhibitor 
treatment using the Stable Isotope Labeling by Amino Acids in Cell culture (SILAC) method 
revealed the quantitative effects of these inhibitor compounds on the whole phosphoproteome. 
To our surprise, these three broadband phosphatase inhibitors displayed very different 
efficiency, with tyrosine phosphorylation significantly boosted but serine/threonine 
phosphorylation much less affected. Additionally, a method to estimate an upper bound of the 
stoichiometry of phosphorylation was introduced by comparing phosphorylation in three 
SILAC conditions: non-treated cells, stimulated cells (e.g. with insulin), and only phosphatase 
inhibitor treated cells. The methods developed here can be used directly in development of 
drugs directed against kinases and phosphatases, key regulators in cancer and other diseases.   
The second project continues with the application of phosphoproteomics techniques. Kinase 
inhibitors influence cellular signal transduction processes and therefore are of great potential 
in rescuing aberrant cellular signaling in tumors. In fact they constitute a significant portion of 
drug developing programs in pharmaceutical industry. With the aim of quantifying the effect 
of kinase inhibitors over the entire signaling network, the second project first set out to study 
two very commonly used kinase inhibitor compounds for MAPKs: U0126 and SB202190. 
Their effect on epidermal growth factor (EGF) signal transduction was quantified and 
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compared using the HeLa cell system. The study confirmed that the MAPK cascades are the 
predominant signaling branches for propagating the EGF signaling at early time points of 
stimulation. These large scale examinations also suggest that U0126 and SB202190 are quite 
specific inhibitors for MAPKs as the majority of regulated phosphopeptides appears to belong 
to the MAPK pathways. In the second part of the project, the effect on phosphoproteome 
changes of the chemical compound dasatinib, which was demonstrated to effectively inhibit 
the constitutively activated fusion protein BCR-ABL and was recently approved for chronic 
myelogenous leukemia (CML) therapy, was quantified in the human CML cell line K562. 
Bioinformatic analysis revealed that the most influenced signal transduction branch was the 
Erk1/2 cascade. Overall more than 500 phosphorylation sites were found to be regulated by 
dasatinib, the vast majority not described in the literature yet. 
The third project compared the proteomes of mouse hepatoma cell line Hepa1-6 with the non-
transformed mouse primary hepatocytes. This was performed by combining the SILAC heavy 
labeled form of Hepa1-6 with the primary hepatocytes. To characterize the features of these 
two proteomes, quantitation information (i.e. protein ratios between the two cell types) was 
used to divide all proteins into five quantiles. Each quantile was clustered according to the 
Gene Ontology and KEGG pathway databases to assess their enriched functional groups and 
signaling pathways. To integrate this information at a higher level, hierarchical clustering 
based on the p-value from the first Gene Ontology and KEGG clustering was performed. 
Using this improved bioinformatic algorithm for data mining, the proteomic phenotypes of the 
primary cells and transformed cells are immediately apparent. Primary hepatocytes are 
enriched in mitochondrial functions such as metabolic regulation and detoxification, as well as 
liver functions with tissue context such as secretion of plasma and low-density lipoprotein 
(LDL). In contrast, the transformed cancer cell line Hepa1-6 is enriched in cell cycle and 
growth functions. Interestingly, several aspects of the molecular basis of the “Warburg effect” 
described in many cancer cells became apparent in Hepa1-6, such as increased expression of 
glycolysis markers and decreased expression of markers for tricarboxylic acid (TCA) cycle. 
Studies in this thesis only provide examples of the application of mass spectrometry-based 
quantitative proteomics and phosphoproteomics in cancer research. The connection to clinical 
research, especially the assessment of drug effects on a proteome wide scale, is a specific 
feature of this thesis. Although this development is only in its infancy, it reflects a trend in the 
quantitative mass spectrometry field. We believe that more and more clinical related topics 
can and will be studied by these powerful methods.  
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1 Introduction 
In this proteomics era, mass spectrometry (MS) is a powerful technology to explore important 
questions in biology. Recent progress in MS has enabled close-to-complete proteome 
measurements1. Quantity comparison has become very precise even without the aid of 
chemical or metabolic labeling. These achievements have encouraged researchers to apply 
MS to various topics in biology and medicine, including cancer research. 
 
1.1  Signal transduction in cancer 
Signal transduction is an inherent molecular mechanism to respond to extracellular 
environmental changes and to maintain cellular homeostasis. Growth factor signaling is a 
canonical paradigm for response to extracellular signals and such processes are involved in 
growth2, differentiation3, 4, development5-7, immune response8, and cell movement9, to name a 
few examples. Signaling involved in cellular homeostasis coordinates intracellular 
organization, ensures survival of normal somatic cells10, 11 and removes senescent or damaged 
cells12, among many other functions. 
 
1.1.1   Signal transduction paradigm 
Signal transduction is a triggered event. It typically consists of three elements: the activator 
which initiates the signal transduction, the effectors which propagate the signal, and the 
attenuators which provide negative feedback and eliminate the signal.  
Epidermal growth factor receptor (EGFR) signaling is a canonical signal transduction 
pathway (Figure 1.1). Ligand binding to the extracellular domain induces EGFR dimerization 
and conformational change. The exposed tyrosine residues of the intracellular kinase domain 
in one monomer are cross-phosphorylated by the other monomer. Phosphotyrosines create 
binding sites and thus bring to the intracellular domain of EGFR numerous SH2 domain 
containing proteins, such as RasGAP, SHP-1, and PI3K. In turn, these proteins recruit more 
signaling molecules to propagate the signal. As a balance, negative feedback loops are 
initiated to attenuate and terminate the signal13, 14. 
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Figure 1.1   A canonical growth factor signal transduction network – the EGFR signaling 
pathway. From Sigma Aldrich Key Resources. 
 
It has been estimated that up to 20% of the human genome encodes signaling proteins15, 16. 
These include 1,543 signaling receptors17, 518 protein kinases18, around 150 protein 
phosphatases19-21  , and more than 1,850 transcription factors17, 22.  
 
1.1.2   Mechanism of signal transduction 
Actions such as conformational change, post-translational modifications, molecular 
interactions, regulated localization, and trafficking are essential to signal transduction. It 
typically is an amplifying process where one upstream effector reacts with multiple 
downstream effectors.  
Phosphorylation is by far the most well studied mechanism of regulation in signal 
transduction. It is also the major subject of this thesis. However, it is noteworthy that research 
in recent years has revealed more and more post-translational modifications as important 
regulatory mechanisms. For example, ubiquitination – the addition of ubiquitin-like molecules 
to lysine residues – is widely recognized as governing protein degradation via the “ubiquitin-
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proteasome pathway”. It also plays a role in protein trafficking, DNA repair and replication, 
and other cellular functions. A related small protein modification – SUMOylation – has been 
demonstrated to be involved in processes like cell cycle progression and apoptosis. As another 
example of an important PTM, acetylation of lysine residue in histone tails generally leads to 
active gene transcription. 
To ensure speed, specificity and efficiency in signal transduction, several mechanisms are 
employed. 
Domain-domain interactions. Structurally conserved protein domains provide recognition 
patterns for biomolecular interactions. Currently the PFAM database documents more than 
3500 domains for Homo sapiens23 and a subset of these are commonly employed in signal 
transduction24. Signaling proteins may contain tandem domains or multiple types of domains 
to facilitate their functions.  
Different dynamics. Reaction dynamics vary for different proteins25, 26 and protein groups27, 28. 
Compared to long-term stimulation, signals lasting for only a few seconds can trigger 
different reaction modes27, 29. Often, similar dynamics are observed among correlating 
proteins, such as components of complexes30, 31. Cells use different signal attenuating 
strategies. While Ser/Thr phosphorylation and tyrosine dephosphorylation are often used to 
quickly attenuate the signal32-34, other long term negative feedbacks are also employed, such 
as transcriptional and translational control, protein turnover, and exocytosis35, 36.  
Compartmentalization and scaffolding. Co-localization concentrates signaling proteins and 
therefore enhances interaction efficiency37. For example, in response to insulin, most proteins 
involved in GLUT4-mediated glucose transport gather in caveolar lipid rafts38. Multiple 
localizations may indicate alternative functions of the same protein. For example, the receptor 
tyrosine kinase Flt3 localized on organelle membranes has different activity from that on the 
plasma membrane30.   
Tissue specific expressions and isoforms. Proteins can be selectively expressed according to 
their function in different tissues and cell types. For example, GLUT4 is expressed 
predominantly in insulin responsive tissues25, 39. It has been estimated that around 40-60% of 
human genes are subjected to alternative-splicing events40, 41. Isoforms may perform different 
functions. For example, PLCγ is the only PLC isoform that contains signal transduction 
domains, indicating its active role in signal transduction42.  
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1.1.3   Altered signal transduction in cancer 
In the homeostatic state, signal transduction pathways form a well coordinated and subtly 
balanced network. However, this balance is distorted in tumors, where cell proliferation and 
survival are strengthened and apoptosis is impaired. Cancer, a malignant form of neoplasm, is 
able to invade normal tissues and metastasize to and grow at distant body sites43.  
Cancer is characterized by self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of apoptosis, limitless replicative potential, tissue invasion and 
metastasis, and sustained angiogenesis44, 45. It is an intractable disease with multiple origins 
and complicated etiology.  
 
1.3.3.1   Relentless cell proliferation in cancer 
Relentless cell proliferation in cancer lesions is a prerequisite for cancer transformation46. 
There are several check points that guard cell cycle progression. The final commitment to cell 
duplication is the transition from G1 phase to S phase. In this process, the retinoblastoma 
protein (pRb) plays a critical role. Inactivation or deletion of pRb can be found in most human 
cancers47, 48. Likewise, p53, the ‘guardian of the genome’, is mutated in most tumors as well 
as Myc, a transcription factor and another critical player in cell cycle47, 48.  
CDKs, which are Ser/Thr protein kinases, are the central engines that propel the cell cycle. In 
contrast, inhibitory proteins such as p21Waf1/Cip1 and p27Kip1 negatively regulate this process. 
In cancer, enhanced activities of CDKs and loss-of-function of p21Waf1/Cip1 and p27Kip1 are 
often reported49. 
 
1.1.3.2   Enhanced cell growth in cancer 
Aberrations in three signaling cascades, Ras, PI3K and mTOR, are considered critical in 
promoting tumor cell growth50. Mutations in the master regulators, such as K-Ras, H-Ras, N-
Ras, and the p110α catalytic subunit of PI3K, are found in most human tumors50. B-Raf 
activity is enhanced in more than 60% of human malignant melanomas, as well as in some 
colon, thyroid and lung tumors51. Furthermore, mutation in one or another PI3K pathway 
component accounts for up to 30% of all human cancers52. Mutations in the negative feedback 
loops also contribute to cancer development. For example, inactivation of the GTPase 
activating protein NF1 leads to the accumulation of GTP-bound Ras, and therefore promotes 
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Ras signaling. Sporadic mutations of PTEN, a lipid phosphatase that balances PI3K signaling, 
are so frequently found in tumors that they are now regarded as the second commonly mutated 
tumor suppressor in humans, right after p5350.  
 
Figure 1.2   The Ras, PI3K, and mTOR activate cell cycle by inhibiting CDK inhibitors (e.g. 
p27Kip1 and p21Waf1/Cip1) and activating cyclins. Modified from New et al. 53. 
 
The mechanisms of the Ras, PI3K and mTOR pathways to enhance tumor growth are 
manifold. First, they activate CDKs and inhibit cell cycle suppressors, thereby drastically 
promoting cell proliferation53, 54 (Figure 1.2).  
 
Figure 1.3   Connection of the three major signaling cascades in promoting neoplasm: Ras, 
PI3K, and mTOR signaling cascades. From Shaw et al. 50. 
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Second, constitutively activated signaling can bypass survival factors, which are required for 
the survival of normal cells. Third, hyper-activated mTOR signaling promotes protein 
synthesis and angiogenesis even under nutrient-deficient conditions55. This ensures synthesis 
of the protein material for tumor cell expansion. Strikingly, these three pathways are tightly 
interconnected (Figure 1.3). They work in concert to promote tumor growth. 
 
1.1.3.3   Suppressed apoptosis in cancer 
Apoptosis or programmed cell death is mainly implemented via caspases46. They can be 
activated by the ligands of the death receptors or by cytochrome c, which is released from 
mitochondria.  In tumors, mutations are reported to suppress apoptosis, for example by 
impairing the release of cytochrome c and therefore violate the major initiating mechanism of 
apoptosis56-59. The transcription factor p53 plays a critical role in apoptosis. It induces 
expression of the cell cycle inhibitor p21waf/cip and the pro-apoptotic protein Bax42 and also 
functions as an exonuclease in DNA damage repair responses60.  
 
1.1.3.4   Other critical signaling pathways in cancer development 
Besides the aforementioned signaling pathways, other critical events in cancer development 
have become increasingly clear. The NFκB signaling pathway bridges cancer with infection 
and chronic inflammation45. Hypoxia induced factors (HIFs) trigger angiogenesis under the 
hypoxia conditions typical of the cancerous microenvironment55. A number of signaling 
factors, including TGF-β, HGF and IGF, can facilitate metastasis61.  
 
1.1.4   Kinases, phosphatases and cancer 
1.1.4.1   Families of protein kinases and protein phosphatases 
Phosphorylation and dephosphorylation are essential for most signal transduction events. 
Sequencing of the human genome and sequence comparison revealed 518 genes encoding 
protein kinases18 and 122 genes encoding protein phosphatases21, 62. 
Protein kinases are among the largest protein families in eukaryotes. By sequence homology 
of their catalytic domains, they can be classified into 9 broad groups, 90 families and 145 
subfamilies18 (Figure 1.4 and Appendix 1). Based on substrate specificity, protein kinases can 
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be divided into Ser/Thr kinases, tyrosine kinases (PTKs), and dual-specificity kinases. While 
the former two types of kinases selectively phosphorylate serine/threonine or tyrosine residues, 
respectively, the dual-specificity kinases can phosphorylate all of them. Large scale 
phosphoproteomics studies reestablished that tyrosine phosphorylation only accounts for a 
small percentage of overall phosphorylation, with a ratio of pSer:pThr:pTyr of 48:7:131. Out of 
the 518 genes, only 90 encode tyrosine kinases. 
 
 
Figure 1.4   Dendrogram of the human kinome. TK: tyrosine kinase group; TKL: tyrosine 
kinase like group; STE: group of homologs of yeast sterile protein kinases; CK1: casein 
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protein kinases; AGC: PKA, PKG & PKC containing group; CAMK: calcium/calmodulin 
dependent protein kinase group; CMGC: CDK, MAP, GSK3 & CLK containing group. 
Adapted from: Cell Signaling Technology.  
 
Protein phosphatases counteract and balance the action of protein kinases. They are generally 
divided into Ser/Thr phosphatases and tyrosine phosphatases (PTPs) (Figure 1.5). 
Interestingly, there are 107 genes encoding tyrosine phosphatases21 while only 15 genes 
encode Ser/Thr phosphatases62. This suggests that dephosphoyration is regulated differently 
for tyrosine and serine/threonine. Indeed, Ser/Thr phosphatases often recruit distinct 
regulatory proteins to achieve substrate specificity. In contrast, most PTPs possess multiple 
domains which mediate their specificity towards substrates. 
  
Figure 1.5   Phosphatase superfamily. (A) Dendrogram of the serine/threonine protein phosphatases, from 
the tyrosine protein phosphatases, from Alonso et al
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 et al.63. (B) Classification of 
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1.1.4.2   Protein kinases and protein phosphatases in cancer 
Over 400 human diseases have been connected to protein kinases. In fact, protein kinases 
especially PTKs, comprise a large fraction of the more than100 dominant oncogenes known to 
date. Aberrations of the 31 receptor tyrosine kinases (RTKs) are frequently found in human 
cancers16. These include Neu/ErbB2 and EGFR in breast and lung carcinomas and Kit/SCFR 
in several highly malignant tumors such as gastrointestinal stromal tumor, acute myeloid 
leukemia, and lung cancer. Aberrations of cytoplasmic PTKs, such as c-Src, c-Abl, JAKs and 
STATs, are also associated with human malignancy.  
Protein phosphatases generally function as negative regulators of signal transduction. 
Therefore, abnormalities of PTPs often promote cancer development. For example, point 
mutations are commonly observed. In one report, six mutated PTPs were found in colon 
cancer, with equal distribution in receptor and non-receptor PTP families34. Strikingly, these 
mutations were mostly located outside the catalytic domains. Another format of abnormality 
is hyper-methylation of the genes for PTPs. Well documented examples include hyper-
methylation-mediated silencing of shp1 and glepp1 64-67. Furthermore, those PTPs which can 
positively regulate signal transduction are also reported to malfunction in malignancy. For 
example, SHP2 is reported to be hyper-active in Noonan syndrome and leukemia68, 69.  
 
1.1.5   Molecular targeted cancer therapies 
The heavy reliance of many cancers on critical proteins, especially kinases and phosphatases, 
has stimulated interest in developing molecular targeted therapies. Clinical demonstration of 
this concept was only demonstrated at the turn of the 21st century, with the introduction of 
Gleevac (see below). To date, a decade’s development has resulted in the successful 
introduction of several inhibitor compounds and antibodies into clinical use. In fact, this 
exciting process is full of reversals, re-discoveries and innovations54. 
 
1.1.5.1   Small molecule inhibitors for kinases and phosphatases 
In the clinic, cyclosporine A has been used as an immunosuppressant for organ transplantation 
surgeries since 1983. It was not until 1991 that its molecular mechanism was revealed – it is 
an inhibitor for phosphatase calcineurin (PP2B)70. Rapamycin, another immunosuppressant 
approved for clinical use in 1999, targeted mTOR with the highest specificity among all 
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inhibitors to date71. Fasudil, which mainly inhibits the Rho-dependent protein kinase Rock, 
was approved in Japan in 1995 for the treatment of cerebral vasospasm71. Certain indirubin 
dyes, included in an ancient Chinese herbal remedy for treating leukemia for hundreds of 
years, were discovered to be potent CDK inhibitors72. 
The examples mentioned above indicate that some kinase or phosphatase inhibitor drugs were 
in use long before the concept of molecular targeted inhibition was articulated. Their success 
alleviated two initial concerns, that inhibitors may not achieve sufficient specificity due to the 
conservation of the catalytic domain in protein kinases, and that they may not be able to 
compete with the highly concentrated cellular ATP (2-10 mM). 
The first inhibitor drug developed with the clear aim of molecular targeting to a specific 
cancer protein is imatinib. It entered human clinical trial in 1996 and was approved for 
clinical use in 200154. The molecular target of imatinib (Gleevac) is BCR-ABL and the drug 
achieved very high remission rates. It also inhibits the PDGF receptor and cKIT and achieved 
80% response in gastrointestinal stromal tumors patients with activating KIT mutations73. 
With its high efficacy, minimum side effects, and short time to approval, imatinib has 
propelled rapid development of other inhibitor compounds. After G-protein-coupled receptors, 
protein kinases are now the second largest group of drug targets in the pharmaceutical 
industry, comprising 20-30% of drug development programs. An up-to-date list of inhibitor 
compounds in clinical use is displayed in Table 1.1. Over 75 protein kinase inhibitors have 
entered advanced human clinical trials, and it is estimated that over 500 other inhibitor 
compounds are in preclinical studies (http://www.kinexus.ca/science/protein_kinases/). 
 
1.1.5.2   Specificity of the small molecule inhibitors  
Most kinase inhibitor compounds are ATP competitive. Many of them are known to target 
more than one kinase71. However, those that achieve high specificity often interact with 
neighboring regions of the ATP binding pocket. This is well demonstrated by the crystal 
structures of SB203580 binding to p38 MAPK and purvalanol binding to CDK254. Crystal 
structures also revealed that imatinib straddles the highly conserved amino-terminal region of 
the activation loop in BCR-ABL and locks the kinase in its inactive conformation74. The 
compound BIRB0796 binds to p38 MAPK in a similar way54. 
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Table 1.1   Kinase inhibitor compounds in clinical use or clinical trials. From Petrelli et al.75. 
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1.1.5.3   Antibody-directed therapy 
Molecular targeted therapies also include other strategies beyond kinase and phosphatase 
inhibitors. Antibody therapy is one of these and increasing in popularity. Antibodies that bind 
to the extracellular domain of RTKs can correct their hyper-active signaling, which is due to 
over-expression or mutation. For example, cetuximab is a monoclonal antibody for EGFR 
which recently received both the FDA (the US Food and Drug Administration) and EMEA 
(the European Medicines Agency) approval to treat head and neck cancers76. Bevacizumab, a 
monoclonal antibody against VEGF, has been approved by the FDA as first line cancer 
therapy that acts against angiogenesis77. 
 
1.1.5.4   Combined and multi-target therapies  
Relapse after kinase inhibitor treatment is frequently seen in the clinic and this has 
encouraged the development of second generation inhibitors78. So far, cancer cells are known 
to engage in at least two strategies to escape the drug’s effects: to generate second mutations 
in the targeted kinases79, 80 or to use other signaling molecules to compensate for the 
suppressed kinases81, 82. As a solution, it is suggested to rationally combine inhibitor drugs 
that can target multiple oncogenes in parallel. For example, combination of imatinib and 
dasatnib for treating chronic myelogenous leukemia (CML) has been proposed83-85.  
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1.2 Mass spectrometry in biology  
Nearly 20 years after its introduction to biology research, MS has become a tremendous 
success86. It has revolutionized the way in which biological information, especially related to 
proteins, can be obtained. With time, MS will become a routine technique to tackle a wide 
variety of biological questions. 
 
1.2.1   General workflow of proteomics 
Mass spectrometry measures the mass to charge ratio (m/z) of molecules. In MS-based 
proteomics, the m/z values of peptides or small proteins are measured, which reflects their 
amino acid composition and possible post-translational modifications. Generally there are two 
measuring approaches, top-down and bottom-up.  
Bottom-up is the most widespread and by far the most successful method in proteomics 
(Figure 1.6). Proteins are enzymatically cleaved at specific sites to yield short peptides which 
typically consist of 6-20 amino acid residues. Mass spectrometers firstly examine the m/z 
value of these peptides (survey scan or MS1 scan) and secondly measure their fragments 
generated inside the mass spectrometer by low energy excitation (MS/MS fragmentation). 
Taking a protein database as a reference, mass spectra can be correlated to amino acid 
sequences with the aid of computer algorithms. The found peptide sequences are then 
assigned to proteins, which ultimate leads to protein identification87. 
In the top-down approach, small intact proteins are ionized and sprayed into mass 
spectrometers where peptide fragments are subsequently generated using one of a variety of 
activation methods such as CID, ECD, SORI, and IRMPD methods (see abbreviation page). 
Top-down proteomics provides an alternative approach in proteomics to peptide based 
approaches. It obtains better sequence coverage of protein identifications and benefits post 
translational modification (PTM) research. However, it is usually limited to small proteins 
with molecular weight up to 30 kDa88 and suffers from the difficulty to solubilize and separate 
proteins in the same way as can be done for peptides.  
Proteomics often deals with complex protein or peptide mixtures. As dynamic range and 
sequencing speed are the limiting factors in the current MS technology28, sample complexity 
has to be reduced. On-line separation with reverse phase chromatography (HPLC) connecting 
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on-line to the mass spectrometer has proven to be a useful separation method (Figure 1.6). 
The C18 reverse phase HPLC column elutes peptide mixtures with linearly increasing organic 
solvent, e.g. acetonitril (MeCN). The gradual elution (typically at a few hundred nanoliter per 
minute) with shallow gradients increases  available sequencing time in the MS. Prior to this 
hydrophobicity-based peptide separation, complex samples can be first be separated by one-
dimensional gel87, isoelectric focusing89, ion-exchange90, 91, molecular size92, and affinity 
binding such as immunoprecipitation27, 93,  IMAC94, 95 and TiO2 enrichment28, 96, 97.  
 
 
Figure 1.6   General workflow for bottom-up MS-based proteomics. Proteomics samples 
come from tissues, cell lines, body fluids, etc. Protein or peptide samples can be fractionated 
by different means to reduce complexity. Depicted is the nanoLC-MS/MS mode, where 
HPLC is coupled to MS via an electrospray ion source and MS/MS fragmentation is 
performed to generate information of peptide primary structure. Computer algorithms match 
mass spectra to amino acid sequences. The outcome of the experiment is a list of identified 
proteins. 
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For less complex samples, static electrospray – called nanoelectrospray –can be used which 
often yields better identification results. In particular static spray is beneficial for some 
modification studies98. 
Data analysis and information mining takes place at the end of the work flow. For example, 
much biological information can be discovered by using different clustering algorithms. 
Frequently used public resources are the Gene Ontology (GO; http://www.geneontology.org/) 
and KEGG pathway databases (http://www.genome.jp/kegg/). Integration of MS-based 
proteomics with other “omics” datasets can provide deeper insights. Examples of these 
valuable datasets are microarray based transcriptome studies99 and protein-protein interactome 
and protein complex studies100, 101. Modeling of molecular networking is emerging. It is 
expected that integration of these large-scale studies will deliver a new kind of biology 
knowledge that cannot be obtained by each of the separate approaches. 
 
1.2.2   Mass spectrometric instrumentation 
Every mass spectrometer consists of an ion source, a mass analyzer, and a detector. 
Peptide/protein ions are generated in ion source typically by one of two soft ionization 
methods: Matrix-assisted laser desorption/ionization (MALDI)102, and electrospray ionization 
(ESI)103. Inside mass spectrometers, peptides ions can be separated according to their 
momentum in magnetic sector104, 105, kinetic energy in electrostatic sector106, velocity in time-
of-flight instruments107, path stability in linear quadrupoles108, as well as orbital frequency in 
quadrupole ion traps109, ion cyclotron resonance mass spectrometer110, 111 , and Orbitrap mass 
spectrometer112. Finally, ions are detected under high vacuum conditions in detectors. Often 
the electron signals are multiplied via secondary electron multiplier.  
Standard parameters to evaluate a mass spectrometer include resolution, mass accuracy, mass 
range or upper mass limit, and ion dynamic range113. 
 
1.2.2.1   Electrospray ionization 
The idea of using electrospray dispersion to produce gas phase ions from solution was first 
introduced by Dole and colleagues in 1968114. Fenn and coworkers realized this idea and 
developed the modern day technique of electrospray ionization mass spectrometry (ESI 
MS)115. Further improvement by Mann and coworkers introduced nanoelectrospray ionization 
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(nanoESI) which is compatible with nano-flow rates (i.e. at the scale of nanoliter-per-minute) 
for minute amount of samples116, 117. 
 
 
Figure 1.7   Electrospray ionization (ESI) process. From Nielsen 118. 
 
In nanoLC ESI (Figure 1.7), a high voltage of several kilovolts is applied to the thin, sharp tip 
of a metal capillary towards the ion source of the mass spectrometer. The orifice of the ion 
source is warmed up to around 150-200 degrees. Liquid flows through the capillary to the tip 
at a slow flow rate, submicroliter-per-minute in typical set ups. The emerging liquid surface 
disintegrates at such high voltages and temperature condition and liquid droplets are formed. 
Because they have very high surface to volume ratios, droplets quickly shrink by evaporation. 
As solutes are of the same charge, electrostatic repulsion leads to explosion of the liquid 
droplets, a phenomenon termed Coulombic fission. Eventually the strong Coulombic 
repulsion overcomes the surface tension of the droplet, and ions are liberated into the gas 
phase and enter the mass spectrometer as single ions119. 
 
1.2.2.2   Linear quadrupole ion trap 
Principles of the LTQ 
The linear quadrupole ion trap (here the LTQ from Thermo Fisher Scientific) contains two 
pairs of orthogonally positioned hyperbolic rods, each segmented into three sections (Figure 
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1.8). The central section is about three times larger than the two end sections. Small slits 
which cut along the rods at the Z axis provide the ion exits. Therefore two detectors are placed 
symmetrically next to the slits to record the radially ejected ions120. Direct current (dc) 
voltages are applied to the opposing rods. These opposing rod pairs receive the same voltage, 
while voltages of the neighboring rods are opposite but of the same amplitude. To trap ions in 
the axial direction (Z axis), different dc voltages are applied to the three sections to create a 
deep electric potential well in the center section. To trap ions in the radial direction (XY-
plane), the major radio frequency (rf) is applied to the rod pairs at both x and y axis, with the 
same amplitude but opposite phases, e.g. Vrf cosωt and -Vrf cosωt. To assist ion activation, 
isolation, and ejection, two phases of supplemental alternating current (ac) voltage are 
imposed on the X-electrode.  
 
 
Figure 1.8   Structure of the two-dimensional linear ion trap. From Schwartz et al.120. 
 
Independent of kinetic energy and initial position, ions obtain stable trajectories within the 
LTQ only if their m/z values locate in certain stable regions in the ion stability diagram121 
(Figure 1.9). For practical reasons, the region A is most interesting, where qmax equals 0.908. 
As seen in equation (1), the m/z value of an ion is inversely proportional to the Mathieu 
parameter qz. From this the minimum m/z values that can be detected in the LTQ is 
determined. The same principle also applies to the three dimensional (3D) ion trap, common 
before the introduction of this 2D ion trap LTQ. This low mass cut-off phenomenon is termed 
“1/3 cut-off” rule for ion traps122. 
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Where m is the ion mass; z is the ion charge; U and V are the potentials of dc and rf, 
respectively; az and qz are Mathieu parameters; ω is the angular frequency of the rf; r0 is the 
radius inscribed, i.e. one-half distance between the opposite rods. 
 
 
Figure 1.9   The ion stability diagram of quadruple ion trap. Mathieu parameters (au, qu) are 
plotted to identify the stability regions in both the XY- (radial) and Z- (axial) directions. 
Regions of simultaneous overlap are marked as A and B. From March et al.109. The Mathieu 
parameters can be calculated by equation (2) and (3). 
 
To analyze trapped ions, the principle of mass-selective instability is employed where the 
main rf voltage is increased at a constant rate. The ramping of the rf potential amplitude 
causes the qz values of all ion species to increase and eventually to exceed the resonance 
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ejection limit (set as 0.88 in some cases120). Ions are radially ejected through the exit slits in 
the X-rods. The supplementary ac signal also contributes to the ion resonance excitation.  
 
Characteristics of the LTQ 
The LTQ offers much better performance over the conventional 3D ion trap120: 15 times 
higher ion capacity, 3 times faster scan rate, up to 100% detection efficiency, and up to 70% 
trapping efficiency. These tremendous advances can be directly translated into improved 
identification results in proteomics study123, 124.  
Performance of the LTQ was examined by Gorshkov et al125. According to their and our 
experience, the  LTQ is able to achieve a mass accuracy of up to 50 ppm and resolution close 
to 1000 (m/z 400), at an ion target value of 5,000 (number of ions filling the trap). In general, 
the LTQ is close to ideal for proteomics studies due to its fast scan rate and high sensitivity. 
However, major caveats of ion traps – when used alone – include low resolution, low mass 
cutoff, and modest mass accuracy. 
 
1.2.2.3   Fourier transform ion cyclotron resonance 
 
Principles of the the FTICR 
Fourier transform ion cyclotron resonance (FTICR) measures ion oscillation frequencies in a 
combined magnetic field and electric field.  Superconducting magnets with field strength of 3 
Tesla or higher are able to provide a uniform, unidirectional and homogeneous magnetic field 
over time. The cubic analyzer cell is composed of six plates (Figure 1.10). Two trapping 
plates are perpendicular to the magnetic field. Two ion excitation plates and two detection 
plates are positioned in parallel to the magnetic field. An ultra-high vacuum of 10-9 to 10-10 
mBar is required for ion detection. 
The force that an ions experience in a combined magnetic and electric field is: 
    
(4)  
)( BvqqEF ⊗+=  
Where q is the ion charge; E is the electric field strength; v is the ion velocity; B is the 
magnetic field strength. 
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Figure 1.10   Structure of the FTICR analyzer cubic cell. B: magnetic field.  
 
Cyclotron motion 
An ion entering the cubic cell experiences zero force in the Z direction, i.e. direction of the 
magnetic field B. However in the direction perpendicular to the magnetic field B, the Lorentz 
force causes the ion to periodically oscillate in circles. The frequency of this motion, termed 
cyclotron motion, is independent of the ion’s kinetic energy but depends on the m/z value of 
the ion: 
    
(5)  m2
B
⋅
⋅
=
pi
qf c  
Where m is the ion mass; q is the ion charge; B is the magnetic field. 
Kinetic energy influences the radius of the cyclotron orbit. The radius scales with the square 
root of the ion’s kinetic energy110, 111.  
 
Trapping motion 
A small (~0.2 V), symmetric positive voltage is applied to the trapping plates to trap positive 
ions. This weak electrical field generates a negative gradient starting from the trapping plates 
towards the center of the cubic cell. Ions oscillate between trapping plates in simple harmonic 
motion, with the trapping motion frequency of 
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 Where m is the ion mass; z is the ion charge; VT is the small symmetric voltage; α and are the 
constants representing the ICR cell geometry. 
 
Magnetron motion 
The electric potential from the two trapping plates distributes among the six plates of the ICR 
cell and generates an uneven potential distribution in space. At the XY-plane, this potential 
decreases when it goes away from the center of the cell. Therefore ions tend to drift away 
from the center with the frequency of 
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Where VT is the small symmetric voltage; α and are the constants representing the ICR cell 
geometry; B is the magnetic field.  
Due to the magnetron motion, the actual detected frequency is the difference between 
cyclotron frequency and magnetron frequency. However, the magnetron frequencies are in the 
order of 1-100 Hz, whereas cyclotron frequencies are of 5 kHz – 5 MHz. Therefore magnetron 
frequencies impose only minute influence on the cyclotron frequencies. As seen from formula 
(7), magnetron frequency is independent of the m/z value, but the radius of ion magnetron 
motion depends on the ion’s initial position within the ICR cell110. 
 
Ion excitation and detection 
For detection purpose, the radius of the ion cyclotron motion has to be as large as possible.  A 
sinusoidal voltage is applied to the excitation plates. If the frequency of ions (
mc ff − ) 
matches the applied rf frequency, the ions will absorb energy and oscillate in resonance. They 
spiral with increasing radius towards the detection plates. After the excitation rf is removed, 
ions cycle in a stable manner and are ready for detection. Their periodic motion produces a 
sinusoidal image signal in the detection plates that can be amplified, recorded and processed 
by Fourier transform algorithm to generate mass spectra.  
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Characteristics of FTICR 
Characteristics of FTICR instruments are listed in Table 1.2. In general, the parts per million 
(ppm) mass accuracy, high resolution, and high dynamic range are the great advantages of 
FTICR. A resolution of 106 was achieved for ions with m/z larger than 1000, by scanning with 
longer transients (>60 seconds) under high vacuum of 10-10 mBar126. However, the drawbacks 
of FTICR have been slow scanning rate, relatively low sensitivity, and space-charge effect. 
Recently larger cubic cells have become commercially available for reduced space-charge 
effect and improved dynamic ranges. 
 
Table 1.2   Characteristics of FTICR MS 
Mass accuracy Resolution @ 1 s scans Sensitivity Dynamic range 
1ppm 100, 000 0.5 fmol 5000 
 
 
1.2.2.4   Orbitrap 
Principles of the Orbitrap 
The Orbitrap is a new type of mass analyzer which resembles the conventional Kingdon trap, 
already known since 1924, to some degree, but embraces a new concept of trapping and 
analyzing ions. 
The Orbitrap is composed of a spindle-shaped inner electrode and a split, barrel-like outer 
electrode (Figure 1.11). The largest inner diameters for the inner electrode and for the inner 
surface of the outer electrode are 8 mm and 20 mm, respectively127. A static, quadro-
logarithmic electrostatic field is generated by the Orbitrap’s axially symmetric electrodes: 
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Where r and z are cylindrical coordinates (z = 0 being the plane of the symmetry of the field); 
C is a constant; k is the field curvature; Rm is the characteristic radius.  
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Ions are pulsed injected into the Orbitrap from an entrance slit offset from its equator. Without 
the need for additional excitation, ions start to oscillate with the combined motions along the 
axial direction (Z direction) and in rotational plane (perpendicular to the Z axis). To squeeze 
ions into tight ion packets and to move them far enough from the out electrodes, an initial 
adjustment by increasing electric fields is performed, typically lasting for 20-100 µs112, 127, 128.  
 
 
Figure 1.11   Cut-away structure of the Orbitrap mass analyzer. From Scigelova et al.129. 
 
Rotational motion and ion trapping 
Due to the electric field, ions experience centrifugal and centripetal forces in the plane 
perpendicular to the Z direction. This rotational motion defines a frequency of 
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Where Rm is the characteristic radius; R is the radius of the circle; ω is the frequency of axial 
oscillations. 
And the radius of the rotation is 
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Where eV is the ion’s kinetic energy; eE is the force due to the electric field which is directly 
radially inward. 
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Equation (10) indicates that, once the field strength is fixed for a certain electric sector, the 
radius of the ion rotational motion depends on the ion kinetic energy. In other words, only 
certain ions with appropriate kinetic energies obtain stable trajectories along the rotational 
plane.  
 
Radial ion motion 
The radial component of the electric field also influences the ion’s orbital trajectory. The 
frequency of the radial motion is described by equation (11). The initial position, as well as 
energy distributions in the rotational and radial directions can directly influence the radial 
motion112. Therefore with time the ion radial motion will go out of phase, with a speed of 
orders of magnitude faster than in the axial direction.  
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Where Rm is the characteristic radius; R is the radius of the circle.  
 
Axial ion motion and ion detection 
Tight ion clouds can oscillate along the Z direction in-phase, with the frequency described in 
equation (12). This axial frequency is independent of kinetic energy, initial position and other 
ion parameters. Therefore it is unique to each given m/z and severs the purpose of ion 
detection and mass measurement112. 
    
(12)  
( )kmq=ω  
Where m is the ion mass; q is the ion charge; k is the field curvature. 
 
Due to the symmetric shape of the electrodes, the image currents generated by the dephased 
rational and radial oscillations in different sections will eventually cancel each other out. 
However, the axial oscillation persists to generate useful signal current, which can be 
translated to mass spectra using the Fourier transform algorithm. 
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Characteristics of the Orbitrap 
Characteristics of Orbitrap are listed in Table 1.3. The Orbitrap ‘inherits’ all the advantages of 
FTICR, i.e. high mass accuracy, high resolution, and high dynamic range while being a much 
smaller instrument and not needing a superconducting magnet. Due to the unique structure of 
the LTQ-Orbitrap instrument, an internal calibration method using a lock-mass can achieve 
sub-ppm mass accuracy130. Compared to the FTICR, the Orbitrap has increased sensitivity and 
much reduced space-charge effects. The latter is due the fact that ions with different kinetic 
energies generate different rotational motions and ions are shielded from each other by the 
central electrode. Ion thin rings with different m/z will disperse out, limiting the columbic 
repulsion effects. 
 
Table 1.3   Characteristics of the Orbitrap MS. 
Mass accuracy Resolution @ 1 s scans Sensitivity Dynamic range 
1ppm 60, 000 0.1 fmol 5000 
 
 
1.2.2.5   Hybrid mass spectrometers to study peptide primary sequences 
Hybrid mass spectrometers are commonly used in proteomics studies. The LTQ-FT and LTQ-
Orbitrap combine the advantages of fast scanning rate and high sensitivity of the LTQ and the 
advantages of high mass accuracy, high resolution, and high dynamic range of the FTICR and 
Orbitrap131, 132. To reduce space-charge effect, automatic gain control (AGC), which delivers a 
constant number of ions per scan, is used in the LTQ before injection into the FTICR or 
Orbitrap. This has been demonstrated to produce highly accurate m/z measurements by 
cancelling space charge effects. The hybrid nature of the instrument also facilitates fast 
peptide fragmentation in space. 
Peptide fragmentation generates very useful information of amino acid sequences. Collision 
induced fragmentation (CID) is the most widely used method. CID introduces low energy 
fragmentation via collision with inert gases (e.g. helium) at energies of some eV. Repeated 
collisions cause peptides to decompose. Breakage of peptides can happen in several modes 
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(Figure 1.12). In our electrospray-LTQ-FT/Obitrap setup of analyzing tryptic peptides, CID 
mostly generates b and y ions.  
 
 
Figure 1.12   Nomenclature for fragment ions133, 134. Peptide back bones are shown with 
amino acid side chains represented with R. CID usually generates y and b ions.  
 
An ion detection cycle in our MS-analysis is composed of two parts, the full scan and the 
peptide fragmentation scan. Precursor ions are scanned in the FTICR or Orbitrap for the entire 
range of m/z values (MS). Ions of interest are then separately isolated and accumulated in the 
linear ion trap for CID peptide fragmentation (MS/MS). By retaining fragment ions of interest 
in the trap via ion selective instability mode, further fragmentation (MSn) can in principle also 
be performed. This has been proven very useful in deriving sequence information from 
phosphorylated peptides135. Recently, multistage activation (MSA) has become available. In 
this special scan mode, the MS/MS/MS fragmentation is generated in the presence of all the 
MS/MS fragments without intervening isolation step. Therefore the resulting mass spectra are 
a combination of MS2 and MS3 fragments. MSA is routinely used in our phosphorylation 
studies. Due to the fast scan rate in LTQ, the MS event in FT/Orbitrap and MSn events in LTQ 
can be easily combined without extending the cycle duty135. 
Other types of fragmentation techniques are also used, such as electron capture dissociation 
(ECD) and electron transfer dissociation (ETD). Electron transfer generates a completely 
different pathway of thermo-energy distribution and peptides tend to fragment at the Cα-NH 
bond. ECD and ETD are suggested to generate complementary mass spectra to those from 
CID136. 
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1.2.3   Quantitative proteomics 
Biological research often requires the knowledge of protein amounts and their changes under 
different conditions. To meet these needs, various quantitation methods have been developed 
in the past few years. MS-quantitation that entirely depends on the signal intensity of 
unlabeled peptides, i.e. label-free quantitation, is just emerging. This method demands a very 
precise and accurate performance of the whole proteomics workflow. In contrast, a large 
group of other methods employ stable isotopes for labeling peptides. They usually better 
tolerate the signal fluctuations in HPLC and mass spectrometers. 
Stable isotope encoding changes the physiochemical properties of the peptides by the least 
possible amount. Protein/peptide samples that are labeled with stable isotopes have shifted 
m/z values when compared to their natural, non-isotope-labeled counterparts but are otherwise 
identical in all respects. Thus, stable isotopes such as 13C, 15N, and 18O do not induce shifts in 
HPLC retention times137. Therefore labeled and non-labeled peptides show up as pairs in mass 
spectra. Their relative intensities can be directly visualized138. Deuterated peptides shift 
slightly from their non-deuterated counterparts139. However, this problem can be corrected if 
quantitation is based on the entire elution profiles of HPLC instead of on a few single 
observations140. Generally, there are three ways to label proteins or peptides with stable 
isotopes (Figure 1.13)141, 142. Metabolic labeling supplies stable isotopes during the growth 
and development of cells138, 143 and organisms144-146. Chemical labeling modifies certain 
amino acid side chains with natural or isotope-labeled reagents147, 148. Enzymatic labeling uses 
trypsin or Glu-C catalyzed incorporation of 18O during protein digestion149, 150. To distinguish 
the labeled and non-labeled forms of peptides by MS, it is recommended to generate a 
minimum of 4 Da difference in the peptide pairs.  
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Figure 1.13   Strategies in mass spectrometry-based quantitative proteomics. Boxes in blue 
and yellow represent two experimental conditions. Horizontal lines indicate the experimental 
step where samples are combined. Dashed lines indicate points at which experimental 
variation and thus quantification errors can occur. From Bantscheff et al.141. 
 
It is advantageous to mix samples at an early stage of the experiment to avoid accumulating 
systematic errors, which can translate into inaccurate quantitation results in the sensitive mass 
spectrometry measurement. From this perspective, metabolic labeling is superior to other 
quantitation methods. Stable isotope labeling with amino acids in cell culture (SILAC) is an 
established method with all the strengths of the metabolic labeling strategy138, 151 (Figure 1.14). 
SILAC labeling utilizes arginine and lysine with heavy elements of 13C, 15N, and 2H. The 
most commonly used forms are 13C6-Arg, 13C615N4-Arg, 2H4-Lys and 13C615N2-Lys. Up to 
three different biological conditions can be compared in a single SILAC experiment and many 
interesting biological discoveries have been obtained using this method151.  
 
Introduction 
32 
 
 
Figure 1.14   SILAC strategy in quantitative proteomics. (A) Two SILAC states are presented. 
One state is labeled with light isotopes (e.g. 12C614N 4-Arg and/or 12C614N2-Lys) and the other 
state with heavy isotopes (e.g. 13C615N4-Arg and/or 13C615N2-Lys). Samples are mixed as early 
as possible to avoid introducing experimental errors. (B) Relative quantities of the peptides 
are visualized in MS spectra. (C) Extracted ion chromatogram indicates that light- and heavy- 
labeled peptides co-elute very well during reverse phase HPLC separation. Modified from 
Ong et al.142. 
 
iTRAQ (an isobaric tag for relative and absolute quantitation) is a chemical labeling method 
which can quantify up to eight different conditions in single experiment 152. A multiplexed set 
of isobaric reagents are used to modify each sample. Differently modified peptides display no 
difference in MS scans due to the isobaric property of the mass tags. However, after peptide 
fragmentation the unique, low-mass reporter ion of each tag (113-121 Da) is displayed in 
MS/MS spectra. Quantitation is therefore carried out in MS/MS spectra rather than MS 
spectra.  
Absolute quantitation is another interesting challenge in quantitative proteomics. Using a 
reference sample with known amount, the aforementioned quantitation methods can be used 
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to deduce the absolute amount of proteins in the sample. Successful examples include the 
precise quantitation of Grb2 copy numbers in HeLa cells by means of absolute-SILAC153.  
 
1.2.4   Phosphoproteomics 
Phosphorylation is thought to occur in one third of the proteome. Early estimates suggest that 
there are over 100,000 phosphorylation sites in human proteome. While ubiquitously 
distributed, phosphoproteins are typically of low abundance. Furthermore, often only a few 
percent of the entire protein amount is present in a phosphorylated form154. Phosphorylation 
governs most signal transduction processes and many other cellular functions. Therefore the 
study of phosphoproteomics is of great importance. 
To enrich the low abundant phosphorylated proteins or peptides, various methods have been 
developed. Chromatographic methods include affinity binding to phospho-antibodies27, 155, 
affinity binding to kinase domains156, metal chelation94, 157, 158, and ion exchange159. Chemical 
modifications of the phosphate group are also used to create affinity tags for purification160-163. 
Engineering proteolytic digestion at the phosphorylation sites is also proposed164, 165. Among 
these, the chromatography methods are most widely adopted due to their high enrichment 
efficiency and experimental simplicity. 
 
1.2.4.1   Antibody-based enrichment 
Tyrosine phosphorylation comprises less than 2% of the cellular phosphorylation events31. 
Fortunately good quality antibodies of phospho-tyrosine (pTyr), such as 4G10 and pTyr100, 
can be employed to enrich pTyr containing proteins or peptides27, 93, 155. Antibodies generated 
against kinase substrate motifs, such as AKT motif, are also used to enrich substrates of 
specific kinases156. 
  
1.2.4.2   Strong cation exchange (SCX) 
SCX is a low resolution but robust enrichment method159, 166. The principle of using SCX in 
phosphopeptide analysis is based on reduced positive charges on the phosphorylated peptides. 
Most tryptic peptides carry one positive charge at each peptide terminus at pH 2.7, as 
specified in the SCX buffer (NH4+ from the N-terminal amino group and the positively 
 charged side chain of trypsin or
the positive charges, effectively reducing the charge state by one, and therefore decrease the 
binding to the SCX column. Generally multiply phosphorylated peptides bind to the column 
with minimum affinity, while non
amino acids (glutamic acid and aspartic acid) can interfere with this strategy. 
coworkers demonstrated large 
fractionation166. 
 
1.2.4.3   TiO2 enrichment 
Titanium dioxide (TiO2) particles 
stress. Their unique amphoteric ion
material to silica in chromatography
phosphates in solution has been revisited.  H
chromatography can achieve very high enrichment efficiency (90%) for phosphopeptides in 
simple samples168. For complex samples, 
acid residues such as glutamic acid and aspa
proposed the use of 2,5-dihydroxy benzoic acid (DHB) to compete with the acidic peptides 
from binding96. Because the binding 
acidic peptides (Figure1.15), this approach has proven to be very successful in large scale 
phosphoproteomic studies31. 
 
Figure 1.15   Comparison of binding capacities to titanium dioxide sphere. The binding 
capacities increase from carboxylic group, DHB, to phosphate group. Adapted from 
(ASMS 2005). 
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 lysine). The negatively charged phosphate group can counter 
-phosphorylated peptides bind strongly. However, acidic 
scale identification of 2,001 phosphopeptides 
are stable with regards to mechanical, chemical and 
-exchange properties suggested their use
167
. In recent years, its specific 
eck and coworkers demonstrated that
however, non-specific binding of the acidic amino 
rtic acid becomes significant. Larsen et al. 
strengths decrease from phosphopeptide to DHB to 
Gygi and 
using SCX 
thermal 
 as an alternative 
affinity to organic 
 TiO2 
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1.2.4.4   Phosphorylation beyond Ser, Thr, and Tyr 
In cells, phosphate groups are predominantly attached to the hydroxyl groups in serine, 
threonine and tyrosine residues. These are termed the O-phosphorylation. There are also a 
variety of other phosphorylation modes in cells154. In N-phosphorylation, phosphate groups 
attach to histidine and lysine. S-phosphorylation occurs on cysteine. Acyl-phosphotates link to 
aspartic and glutamic acid. New types of phosphorylation have been reported, such as N- or 
O- phosphorylation on hydroxyl-lysine.  
In our phosphoproteomics workflow, acid conditions are employed. This can lead to general 
hydroxylation of most uncommon phosphorylations, e.g. histidine phosphorylation169. To 
investigate those phosphorylation events, basic buffer conditions plus negative ion mode are 
recommended.  
 
1.2.4.5   Quantitative phosphoproteomics 
The recent years have witnessed a breakthrough in phosphoproteomics, such that hundreds or 
thousands of phosphorylation sites can be obtained in single experiments31, 94, 96, 159, 166. Most 
of these studies contain qualitative information of phosphorylation site identifications rather 
than quantitative information. 
The first large scale quantitative, site specific and time-resolved phosphoproteomics study 
was reported by Olsen et.al, where the phosphoproteome changes after EGF stimulation were 
quantified at several time points31. In that study, phosphorylation distribution among Ser, Thr 
and Tyr residues was measured. Dual phosphorylation in kinase activation loops were 
captured, which directly visualized the activation state of the enzymes. Time-resolved studies 
revealed trafficking of phosphoproteins between cytoplasm and nucleus (e.g. STAT5 and 
MAPK1/3). Clustering of phosphopeptides based on their reaction kinetics indicated 
functional groups. Rich biological information was mined from the long list of 
phosphorylated proteins and sites. This work clearly demonstrated the strength of quantitative 
phosphoproteomics.  
Based on the work of Olsen et al, we established a general workflow of quantitative 
phosphoproteomics, which is depicted in Figure 1.16. 
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Figure 1.16   The general workflow of mass spectrometry-based phosphoproteomics. 
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2 Aim of the Study 
 
2.1 Cancer cell line to evaluate inhibitors for kinases and phosphatases 
SILAC-based quantitative phosphoproteomics was previously demonstrated to be a powerful 
technique to decipher phosphorylation changes after growth factor stimulation in cell lines 31. 
In principle, essentially the same technique can be applied to very practical topics such as the 
effect of inhibitor compounds used in everyday research and clinics.  
In this thesis, project 1 is designed as a proof-of-principle study to quantify the effects of 
several commonly used phosphatase inhibitors in laboratories. Meanwhile it is a technology-
centered study, with the aim to analyze the phosphoproteome in depth. Project 2 is designed 
to tackle the effects of some described kinase inhibitors on the entire signaling network, 
including one clinical drug.   
 
2.2 Liver cell model to assess normal and transformed cells 
Elucidation of the properties of transformed cells is a long standingtopic in cancer research. 
Some of these cell lines were derived from tumor tissues, and therefore should retain most 
properties of the tumors. Project 3 is designed to characterize the phenotypes of transformed 
cancer cell line with comparison to primary, non-transformed cells.  
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3 Materials and Methods 
3.1 Cell models 
3.1.1   Immortalized cell lines 
Mouse hepatoma cell line Hepa1-6 
Hepa1-6 was derived from the transplantable hepatoma BW7756, which was chemically 
introduced in C57LBL/6 mice. These cells are adherent and grow as monolayer in culture. 
Hepa1-6 is thought to maintain the major properties and functions of liver, such as secreting 
several liver-specific products including albumin, alpha1-antitrypsin, alpha-fetoprotein, and 
amylase170. As demonstrated by several studies, Hepa1-6 has poor immunogenicity171, 172. It is 
highly sensitive to adenovirus infection and the antisense treatment targeting the oncogene 
IGF-1. It is highly sensitive to adenovirus infection and susceptible to viral replication, 
progeny production and cytopathic effect. Therefore it has become a popular tumor model for 
experimental immunotherapy studies.  
 
Human epithelial  carcinoma cell line HeLa 
HeLa is descended from cervical carcinoma transformed by human papillomavirus 18 
(HPV18) in a female patient. Rearrangement of chromosomes was observed.  They have a 
modal chromosome number of 82, with four copies of chromosome 12 and three copies of 
chromosomes 6, 8, and 17. HeLa cells are adherent and maintain contact inhibition in vitro. 
 
Human myelogenous leukemia cell line K562 
K562 was the first human immortalized myologenous leukemia line to be established. It 
originated from a female CML patient in blast crisis phase and contains the e14a2 fusion 
protein BCR-ABL. This fusion protein is the product of the Philadelphia chromosome which 
is generated by fusing the long arms of chromosome 9 and 22. These two chromosomes 
encode ABL and BCR, respectively. BCR-ABL exhibits constitutive tyrosine kinase activity 
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of ABL and has been proven to be essential in CML. Therefore K562 cells are tumor models 
for experimental CML studies.  
K562 cells exhibit a second reciprocal translocation between chromosome 15 and 
chromosome 17. They resemble both undifferentiated granulocytes173 and erythrocytes174. 
They are deficient in major histocompatibility complex (MHC) and they lack herpesviruses. 
K562 cells are rounded and grow in suspension.  
 
3.1.2   Primary hepatocytes 
Isolation and culture of mouse hepatocytes were performed according to standard operation 
procedures established in the German HepatoSys Network and briefly summarized here175.  
Briefly, six to twelve weeks old B6 mice were used. The use of mice for hepatocyte isolation 
has been approved by the animal experimental committees and animals were handled and 
housed according to specific pathogen free conditions. Anesthesia was achieved by 
intraperitoneal injection of 5mg/100mg body weight ketamine hydrochloride 10% (115.34 
mg/ml; Essex Tierarznei, Munich, Germany) and 1mg/100mg body weight xylazine 
hydrochloride 2% (23.32 mg/ml; Bayer Leverkusen). HANKS solution I was produced by 
supplementation of BASAL HANKS solution (8 g NaCl, 0.4 g KCl, 3.57 g Hepes, 0.06 g 
Na2HPO4 x 2 H2O, 0.06 g KH2PO4 in 1 L distilled H2O, adjusted pH to 7.4, sterilized) with 
2.5 mM EGTA, 0.1% glucose and penicillin/streptomycin at a dilution of 1 : 100. HANKS 
solution II was produced by supplementation of BASAL HANKS solution with 0.3 mg/ml 
collagenase CLSII and 5 mM CaCl2. Hanks solutions I and II were prewarmed in a 42°C 
waterbath. Collagenase was added immediately prior to liver perfusion. After shaving and 
cleaning the abdomen under sterile conditions, the abdominal cavity was opened and the 
portal vein was cannulated with a 24G catheter. A silicon tube (diameter 2.4 mm) was 
connected to the catheter and HANKS solution I was infused via a peristaltic pump at a flow 
rate of 8 ml per minute After starting the peristaltic pump, the vena cava and the right heart 
ventricle were incised to permit sufficient outflow. The liver was perfused with solution I for 
5 minutes, followed by HANKS solution II for 5-7 minutes. Correct placement of the portal 
vein catheter is evidenced during perfusion by the steady and even change from dark red-
brown to a light brown color in all liver lobes. Following perfusion the liver was transferred to 
a sterile Petri dish and the gall bladder was removed. The following steps were performed in a 
sterile hood. The liver capsule was carefully removed using a pincette. Gentle shaking 
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disintegrated the perfused liver, yielding a suspension of single cells, some cell clumps and 
cell debris. The suspension was placed onto a 100 µm cell strainer and was filtered through 
the mesh by gravity flow. The suspension was transferred to a 50 ml Falcon tube and washed 
twice with Williams E medium (room temperature). Cells were centrifuged at room 
temperature at 37.5 x g for 2 minutes in a cell culture centrifuge. The cells were resuspended 
in Williams medium E and the percentage of intact cells was determined by staining an 
aliquot with trypan blue. On average 70-80% of the cells were viable.  
Hepatocytes were placed on collagen coated tissue culture dishes in FCS cell culture  medium 
(William´s medium E supplemented with 10 % FCS, 100 nM dexamethasone, 2 mM L-
glutamine and 1% penicillin/streptomycin solution) and kept in a humidified cell culture 
incubator at 37°C and 5% CO2 (Figure 1). For 6 cm (diameter) tissue culture dishes 
hepatocytes were plated at a density of 2 x 106 cells/dish in 3 ml FCS-culture-medium. After 4 
h of incubation hepatocytes should be attached to the collagen coated dish. Subsequently, the 
FCS cell culture medium was removed and replaced by serum free cell culture medium 
(William´s medium E supplemented with 100 nM dexamethasone, 2 mM L-glutamine and 1% 
penicillin/streptomycin solution).  
In project 3, after cultivation for 14 hours, the primary hepatocytes were placed on ice and the 
medium was removed. The cells were lysed in modified RIPA buffer.  
 
Materials for isolation and culture of primary hepatocytes: Ultra pure bovine serum 
albumin (BSA), dexamethasone and insulin were obtained from Sigma (Deisenhofen, 
Germany). Fetal calf serum (FCS), penicillin/streptomycin (10.000 U/ml - 10mg/ml) and L-
Glutamin from Gibco (Paisley, Scotland) and William´s medium E (WME) from Biochrom 
(Berlin, Germany). Materials used for hepatocyte isolation and culture were  Abbocath-T 18G 
(Venisystems, Abbott, Ireland),  Peristaltic pumps (Reglo Digital; Isamtech, Zürich, 
Switzerland), 100 µm meshcell strainers (Becton-Dickinson, Heidelberg), collagen I coated 6-
well-plates (Becton-Dickinson, Heidelberg) and tissue culture centrifuges (Labofuge M, 
Heraeus, Stuttgart, Germany). All other chemicals of analytical grade were obtained from 
Merck (Darmstadt, Germany). 
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3.1.3   Cell culture 
Hepa1-6 and HeLa cells were obtained from the American Type Culture Collection (ATCC). 
K562 cells were kindly provided by Henrik Daub. General cell culture conditions were 37 ºC, 
5% CO2, and humidified atmosphere. 
Hepa1-6 and HeLa cells were cultured in DMEM medium (4.5 g/l glucose) supplemented 
with 10% fetal bovine serum, 1% (10 mg/ml) streptomycine / (10,000 U/ml) penicillin, 1% L-
glutamine, and 4.5 g/l glucose. Cells were seeded with 20-30% density and were split or 
harvested when the cell density reached around 90%.  
K562 cells were cultured in suspension in RPMI medium supplemented with 10% fetal 
bovine serum, 1% (10 mg/ml) streptomycine / (10,000 U/ml) penicillin, 1% L-glutamine, and 
4.5 g/l glucose. Cells were seeded with the density of 0.2 x 106 cells/ml, and were split or 
harvested at the density of 1-1.2 x 106 cells/ml. 
The following forms of stable isotope-labelled arginine and lysine were used: L-13C6-arginine 
(Arg6), L-13C615N4-arginine (Arg10), L-2H4-lysine (Lys4), and L-13C615N2-lysine (Lys8). 
Normal arginine and lysine used were: L-12C614N4-arginine (Arg0) and L-12C614N2-lysine 
(Lys0). To generate double encoding SILAC conditions, normal medium deficient in arginine 
and lysine was supplemented with Arg10 and Lys8 for the “heavy” condition, or with Arg6 
and lys4 for the “medium” condition, or with Arg0 and lys0 for the “light” condition. Final 
concentrations of arginine are 28 mg/l in DMEM and 84 mg/l in RPMI. Final concentrations 
of lysine were 73 mg/l in DMEM and 49 mg/l in RPMI. In each SILAC condition, medium 
was supplemented with 10% dialyzed fetal bovine serum with 10 kDa cutoff, 1% (10 mg/ml) 
streptomycine / (10,000 U/ml) penicillin, and 1% L-glutamine.  
SILAC cell culture was essentially the same as described for normal cell culture, except that 
SILAC medium and dialyzed FBS were used. Generally, more than 95% incorporation of the 
labelled amino acids can be achieved after 6 passages of cell proliferation. 
 
Materials for cell culture: DMEM and RPMI medium were obtained from Gibco BRL. 
Medium without Arg and Lys was obtained from PAA Laboratories and SAFC Biosciences. 
L-arginine, L-lysine, L-13C615N4-arginine and L-13C615N2-lysine were purchased from Sigma-
Aldrich. Fetal bovine serum and dialyzed fetal bovine serum dialyzed were obtained from 
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Invitrogen. L-glutamine (200 mM in 0.85% NaCl) and streptomycin (10 mg/ml)/penicillin 
(10,000 U/ml) were products of Invitrogen. 
 
3.1.4   Preparation of inhibitor compounds 
Calyculin A, deltamethrin, and Na-pervanadate were prepared freshly before the experiment. 
To prepare stock solutions, calyculin A was dissolved in DMSO to 100 µM and deltamethrin 
was dissolved in DMSO to 10 mM. In project 1, these two phosphatase inhibitors were 
applied to cells with final concentrations of 100 nM for calyculin A and 10 µM for 
deltamethrin. To prepare Na-pervanadate, 30% H2O2 was diluted in 20 mM HEPES, pH 7.3 to 
100 mM, then mixed with an equal volume of 100 mM sodium orthavanadate. After five 
minutes, a scoop of catalase was added to the pervanadate stock to neutralize extra H2O2. In 
project 1, Na-pervanadate was applied to cells to a final concentration of 0.5 mM.  
The 10 mM stock solutions of U0126 and SB202190 were prepared by dissolving the 
chemicals in DMSO. In project 2, these two kinase inhibitors were applied to cells with final 
concentrations of 10 µM. Dasatinib dissolved in DMSO was kindly provided by Henrik Daub. 
 
Materials of inhibitor compounds: calyculin A was purchased from Millipore. Deltamethrin 
was purchased from Merck. U0126 was product from Promega. Na-orthovanadate, catalase 
and SB202190 were obtained from Sigma. 
 
3.1.5.   Cell stimulation, harvest and protein recovery 
Cell stimulation in project 1:  
In the double encoding SILAC experiment (Figure 4.1.2), Arg10 and Lys8 labeled Hepa1-6 
cells were treated with 100 nM calyculin A, 0.5 mM pervanadate and 10 µM deltamethrin for 
10 minutes under 37 ºC.  Arg0 and Lys0 labeled cells were left untreated. 
In the triple encoding SILAC experiment (Figure 4.1.17), cells were serum-starved for 24 
hours. Arg0 and Lys0 labeled Hepa1-6 were left untreated. Arg6 and Lys4 labeled cells were 
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stimulated with 100 nM insulin for 5 minutes. Arg10 and Lys8 labeled cells were treated with 
100 nM calyculin A and 0.5 mM pervanadate for 10 min (no deltamethrin). 
 
Cell stimulation in project 2:  
HeLa cells were serum-starved for 16 hours.  Arg10 and Lys8 labeled HeLa cells were 
stimulated with 10 µM kinase inhibitor (U0126 or SB202190) for 20 minutes. Then in the 
presence of the inhibitor compound, 150 ng/ml EGF was added to the medium for another 15 
minutes. Arg6 and Lys4 labeled HeLa cells were stimulated with 150 ng/ml of EGF for 15 
minutes. Arg0 and Lys0 labeled HeLa cells were left untreated. 
To harvest cells, they were washed with ice cold PBS for two times and lysed in modified 
RIPA buffer containing 1% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 1mM EDTA, 
50 mM Tris, pH 7.5, 1 mM sodium orthavanadate, 5 mM NaF, 5 mM beta-glycerophosphate 
and protease inhibitors. 660 µl of lysis buffer was added to each 15 cm dish. The lysates were 
kept cold and centrifuged at 17,000g for 15 minutes to pellet cellular debris.  
To recover proteins by acetone precipitation (used in project 1 and 2): Supernatant was 
collected and mixed with four volumes of ice cold acetone to precipitate proteins. The cellular 
debris was digested with benzonase in urea buffer containing 6 M urea, 2 M thiourea and 
10mM Hepes pH 7.5. Dissolved proteins were precipitated by adding four volumes of ice cold 
acetone. Precipitated proteins were collected by centrifugation and dissolved in urea buffer. 
Concentration of the dissolved proteins was measured by the Bradford method (A590nm). Equal 
amounts of protein from each SILAC condition were mixed accordingly.  
To recover proteins by methanol/chloroform precipitation (used in project 3): After centrifuge 
at 17,000g for 15 minutes (as described above), supernatant was collected and a Bradford 
method (A590nm) was used to determine the protein concentrations. Equal amount of the 
proteins from the primary hepatocyte sample and Hepa1-6 sample were mixed, resulting in 
100 µg proteins in total. Protein mixtures were added with four volumes of methanol, one 
volume of chloroform and three volumes of distilled water in a sequential manner. The 
addition of each solvent was followed by a short vortex. After centrifugation of 20,000g for 1 
minute, proteins were focused between organic and inorganic phases. The aqueous phase was 
discarded. Four starting volumes of methanol were added to the protein pellet followed by a 
short vortex. After spinning at 20,000g for 2 minutes, methanol was removed and the protein 
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pellet was air-dried. Precipitated proteins were redissolved in a buffer containing 6 M urea, 2 
M thiourea, 10 mM Hepes, pH 7.5. 
 
Materials: Insulin was purchased from Sigma Aldrich. EGF was from Millipore. Benzonase 
was from Merck. Protease inhibitors (complete tablets) were purchased from Roche 
Diagnostics. If not specified, chemicals were purchased from Sigma Aldrich. Solvent was 
obtained from Fluka, Merck, Riedel de Haen, and BioRad companies.  
 
3.2 Proteome mapping 
3.2.1   Sample preparation 
Protein digestion 
For protein in-solution digestion into peptides, the proteins were reduced with 1 mM 
dithiothreitol, alkylated with 5.5 mM iodoacetamide in dark, and digested for four hours with 
endoproteinase Lys-C (1/100 w/w). After diluting four times with Milli-Q water and adjusting 
to neutral pH with 20 mM ammonium bicarbonate, samples were digested overnight with 
sequencing grade modified trypsin (1/100 w/w). The digestion was quenched by adding 
trifluoroacetic acid (TFA) to reach pH <3. Chemicals and enzymes for protein digestion were 
dissolved in 20 mM ammonium bicarbonate. All incubation steps were performed at room 
temperature.  
For protein in-gel digestion into peptides, protein samples were resolved on a NuPAGE 4%-
12% Bis-Tris SDS-PAGE gel (Invitrogen). The gel was stained with the Colloidal Blue 
staining Kit (Invitrogen) for visualization. Gel slices were excised. Each gel slice was cut into 
1 mm3 cubes, washed with 1:1 (v/v) 50 mM ammonium bicarbonate and 50% ethanol. 10 mM 
dithiothreitol was applied at 56ºC for reduction and 55 mM iodoacetamide at 37ºC for 
alkylation in dark. After wash, the gel pieces were dehydrated with 100% ethanol followed by 
rehydration with 12.5 ng/µl trypsin (Promega) in 50 mM ammonium bicarbonate. Trypsin 
digestion was performed overnight at 37ºC. After digestion, supernatants were transferred to 
fresh tubes, and the remaining peptides were extracted by incubating gel pieces two times 
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with 30% MeCN in 3% trifluoroacetic acid (TFA), followed by dehydration with 100% 
MeCN.  
 
Isoelectric focusing to separate peptide mixtures 
Peptides were separated based on their isoelectric points in the Agilent 3100 OFFGEL 
Fractionator and the 3100 OFFGEL Low Res Kit, pH 3-10 according to the manufacturer. 
Peptides were focused for 20 kVh at maximum current of 50A and maximum power of 200 
mW. Each peptide fraction was mixed 10 µl solvent containing 30% MeCN, 5% acetic acid 
and 10% TFA. The resulting solution was loaded into C18 reverse phase StageTips176. 
 
StageTip purification 
StageTips 176, 177 were prepared by punching out small discs of C18 Empore filter using a 22 G 
flat-tipped syringe and ejecting the discs into P200 pipette tips. The C18 Empore column was 
conditioned by methanol and equilibrated in 0.5% acetic acid, 0.1% TFA in water. Peptide 
samples were adjusted to pH<2.5 and forced through the C18 Empore column. The column was 
washed once with 0.5% acetic acid, 0.1% TFA in water. Peptides were eluted from the 
StageTips by applying 80% MeCN, 0.5% acetic acid. Samples were dried in a SpeedVac to 3 
µl and mixed with equal volume of solvent containing 2% MeCN and 1% TFA. 5 µl samples 
were applied for LC-MS/MS analysis.  
 
Materials: Chemicals for the ‘in solution’ digestion were purchased from Sigma-Aldrich. 
Solvent was obtained from Fluka, Merck, Riedel de Haen, and BioRad companies. 
Endoproteinase Lys-C was obtained from Waco and sequencing grade modified trypsin was 
from Promega. Agilent 3100 OFFGEL Fractionator and 3100 OFFGEL Low Res Kit, pH 3-10 
were purchased from Agilent. For producing StageTips, 3M High Performance Extraction 
Disks C18 was obtained from Varian. 
 
Materials and Methods 
46 
 
3.2.2   Mass spectrometric methods 
C18 RP-HPLC separation 
The peptide mixture was separated by nanoscale C18 reverse-phase liquid chromatography 
(Agilent 1200; Agilent Technologies, Waldbronn, Germany) coupled on-line to a 7-T LTQ-
FT or LTQ-Orbitrap mass spectrometer (Thermo Electron, Bremen, Germany) as described178. 
The HPLC is comprises of a solvent degasser, a nanoflow pump, and a thermostated micro-
autosampler. The C18 reverse-phase column, where the chromatographic separation of the 
peptides took place,  is a 20-cm fused silica emitter with 75-µm inner diameter (Proxeon 
Biosystems) packed in-house with methanol slurry of reverse-phase ReproSil-Pur C18-AQ 3-
µm resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) at a constant pressure (50 bar) 
of helium. Samples were picked up by the autosampler and injected to the C18 reverse-phase 
column with a flow rate of 500 nl/min for the first 22 minutes. In the following, peptides were 
eluted at 250 nl/min with an actual separating gradient of 2-40% solvent (80% MeCN in water, 
0.5% acetic acid) over 90 min. The eluate was on-line electrosprayed into the mass 
spectrometer via a nanoelectrospray ion source (Proxeon Biosystems, Odense, Denmark).  
 
 
LC-MS/MS, Top 5 ion sampling  
The mass spectrometers were operated in positive ion mode and employed a data-dependent 
automatic switch between MS and MS/MS acquisition modes. In the LTQ-FT setup, after 
accumulating a target value of 5, 000,000 ions in the LTQ, a full scan was acquired in the 
FTICR analyzer with resolution r=100,000 at m/z 400. In LTQ-Orbitrap analysis, the target 
value was 1,000,000 for full scan in Orbitrap analysis at a resolution r=60,000 at m/z 400. In 
each cycle, full scan determined the five most intense ions from the range 300-1800 m/z. 
These five corresponding ions were next accumulated in the LTQ for sequential fragmentation. 
Total cycle time (full scan to full scan) was approximately 3 s. Fragmentation in the LTQ was 
induced by collision-induced dissociation with a target value of 5,000 ions. Former target ions 
selected for MS/MS were dynamically excluded for a period ranging from 60 to 300 s. The 
actual exclusion time was slightly adjusted according to samples. 
The general mass spectrometric conditions were: spray voltage, 2.2 kV; no sheath and 
auxiliary gas flow; ion transfer tube temperature, 150-180ºC; normalized collision energy 
Materials and Methods 
47 
 
using wide-band activation mode; 35% for MS2. Ion selection thresholds were: 500 counts for 
MS2. An activation q = 0.25 and activation time of 30 ms was applied in MS2 acquisitions.  
 
Internal calibration using lock mass 
To improve mass accuracy for identification, the “lock mass” option was utilized in both MS 
and MS/MS scans as described previously130. This method makes use of the 
polydimethylcyclosiloxane (PCM) (Si(CH3)2O)) ions generated in the electrospray process 
from ambient ion. The protonated PCM ions are with m/z of 445.120025, and in MS/MS 
mode with m/z of 429.088735. The lock mass was injected into the C-trap with a set “ion gain” 
achieving 10% of the target value of the full mass spectrum. The time of accumulation, 
isolation, and transfer into the C-trap of the lock mass was estimated to be a few ms and did 
not induce any obvious extension of ion cycle time. 
 
Materials:  Nanoscale C18 reverse-phase liquid chromatography (Agilent 1100, Agilent 1200) 
was from Agilent Technologies (Waldbronn, Germany). Nanoelectrospray ion source was 
from Proxeon Biosystems (Odense, Denmark). Reverse-phase ReproSil-Pur C18-AQ 3-µm 
resins were from Dr. Maisch GmbH (Ammerbuch-Entringen, Germany). 
 
 
3.3 Phosphoproteome mapping 
3.3.1   Sample preparation 
Immunoprecipitation of tyrosine phosphorylation proteins 
Immunoprecipitation of tyrosine phosphorylated proteins using agarose-conjugated antibodies 
of 4G10 and pTyr-100 was performed as described before93. Cells were lysed with modified 
RIPA buffer and centrifuged with 17,000g for 15 minutes, as described in section 3.1.5.  The 
supernatant was used for immunoprecipitation. Briefly, non-specific binding proteins were 
pre-cleaned with Protein A (Sigma) beads and, following 2 hours incubation with 4G10 
antibody, p-Tyr-100 antibody was added for an additional 4 hours. The incubation was 
performed at 4oC. Proteins were eluted from the beads with 3 times 1ml urea buffer. The 
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eluate was directly subjected to in-solution digestion. To collect the proteins not being eluted, 
the antibody beads were boiled in 70oC SDS-buffer for 10 minutes. SDS-PAGE was 
performed on a NuPAGE 4%-12% Bis-Tris gel (Invitrogen). In the triple encoding SILAC 
experiment in project 1 (Figure 4.1.17), the gel lane was cut into 4 large slices. Proteins were 
digested in-gel with trypsin, as described in section 3.2.1. 
 
Crude fractionation of phosphopeptides by SCX 
To separate phosphopeptides from non-phosphorylated peptides, the strong cation exchange 
(SCX) method was employed179. 10-20 mg of proteins was digested in-solution and the 
peptide mixtures were adjusted by TFA to pH 2.7. Precipitates were cleared by centrifuging at 
17000g for 10 min. Peptide solution was then loaded onto a 1 ml Resource S column (GE 
healthcare) connected to the Äkta Purifier chromatography system (Amersham Biosciences). 
The loading was performed in solvent A (5 mM KH2PO4, 30% MeCN, 0.1% TFA, pH 2.7) at 
a flow rate of 1 ml/min. During the loading step, flow-through solution was collected. 
Peptides bound to the column were separated with a linear gradient of 0-30% salt-containing 
solvent B (5 mM KH2PO4, 30% MeCN, 350 mM KCl, 0.1% TFA, pH 2.7). The separation 
lasted for 30 min. In total fifteen 2-ml fractions were collected by an automated fraction 
collector.  
 
Phosphopeptide enrichment by TiO2 
Phosphopeptide enrichment by TiO2 beads was essentially as described31 with slight 
modifications. TiO2 beads were pre-incubated with 30 g/L 2,5-dihydroxybenzoic acid DHB in 
80% MeCN and 0.1% TFA. From this 1:1 TiO2 beads slurry, 10 µl was added to each sample 
and rotated end-over-end for 30 min. After one time wash with 1 ml 30% MeCN / 1% TFA 
and one time with 1 ml 50% MeCN / 1% TFA, bound peptides were eluted from beads with 
200 µl NH4OH in 40% MeCN (pH>10.5). Eluates were immediately neutralized in 30% 
MeCN  / 3% TFA solvent. Samples were dried down almost to completion and reconstituted 
in 2% MeCN / 1% TFA for LC-MS/MS analysis. 
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Materials: 4G10 agarose conjugated antibody was purchased from Biozol. Phospho-tyrosine 
mouse mAb (P-Tyr-100) was purchased from New England. Protein A agarose conjugated 
beads were products of Sigma Aldrich. NuPAGE 4%-12% Bis-Tris gel and running buffer 
(MOPS) were obtained from Invitrogen.1 ml Resource S column (GE healthcare) connected 
to the Äkta Purifier chromatography system (Amersham biosciences). Chemicals were 
products of Sigma Aldrich. Solvent was obtained from Fluka, Merck, Riedel de Haen, and 
BioRad companies.  
 
3.3.2   Mass spectrometric methods 
LC-MS/MS method, multi-stage activation 
The mass spectrometers were operated in positive ion mode and employed a data-dependent 
automatic switch between MS and MS/MS acquisition modes. In the LTQ-FT setup, full scan 
mass spectra were acquired at a target value of 5, 000,000 ions with resolution r=100,000 at 
m/z 400. In the LTQ-Orbitrap setup, full scan was acquired at a target value of 1, 000,000 
ions with resolution r=60,000 at m/z 400. For complex samples, a total cycle scan comprised 
of 3 mass ranges was applied: m/z 350-1050, 850-1850, and 350-1850. The top 5 most intense 
ions from the first 2 ranges were selected for fragmentation in the LTQ, whereas in the last 
range the top 7 most intense ions were selected. Fragmentation in the LTQ was induced by 
collision-induced dissociation with a target value of 5,000 ions.  
For accurate mass measurement, the “lock mass” function was enabled for both MS and 
MS/MS scan modes. To improve the fragmentation of phosphopeptides, the multi-stage 
activation algorithm180 in the Xcalibur software was enabled for each MS/MS spectrum. 
When a neutral loss of 97.97, 48.99, or 32.66 Thomson (Th) was detected following 
activation of the precursor ion, the neutral loss peptide fragments were further fragmented180 
to generate  a variety of structurally informative fragments. Product ions produced during the 
initial activation of isolated precursor ion (MS/MS) and all subsequent neutral loss activations 
(pseudo MSn) were simultaneously stored, resulting in “composite” mass spectra for peptide 
identification.  
Former target ions selected for MS/MS were dynamically excluded for a period ranging from 
60 to 300 s. The actual exclusion time was slightly adjusted according to samples. The general 
mass spectrometric conditions were essentially the same as described in section 3.2.2. 
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3.4 Mass spectrometric data analysis 
MaxQuant is an in-house built mass spectrometric data processing software140. It consists of 
three components: Feature detection and peptide quantitation (Quant.exe), Identification and 
validation (identify.exe), and Visualization (Viewer.exe). It develops an entire set of 
algorithms in detecting peaks, isotopes and SILAC partners, in quantifying relative peak 
intensities of SILAC partners, as well as in performing statistics to large scale proteomic 
datasets. Its strategy in using different charged states of the same peptide for non-linear re-
calibration and those well identified peptides for global mass re-calibration has lead to an 8-
fold improvement in mass accuracy. This helps to rescue those identifications which would 
otherwise fall out of the required mass accuracy window and generally improves 
identification statistics. Different from conventional method, detection of SILAC partners in 
MaxQuant is performed before the identification and therefore they can be classified into 
groups such that heavy amino acid labeling can be treated as a fixed modification. This 
strategy significantly shortens the time for database search, where too many variable 
modifications often become a bottleneck in deriving results in time. Besides, the new strategy 
strictly constrains the possibility of mismatch. 
 
3.4.1   Identification 
Raw MS spectra were processed in Quant.exe and the derived peak list was searched with the 
Mascot search engine (Matrix Science, London, UK) against concatenated database 
combining forward database (the International Protein Index (IPI)  protein database added 
with 27 commonly observed contaminants) and the reverse database (reversed sequences of 
all proteins from the forward database). For all mouse samples (Hepa1-6 cell line and primary 
hepatocytes) studied in this thesis, the IPI mouse protein database version 3.24 was employed, 
which records 52,326 proteins. For all human samples (HeLa and K562 cell line), IPI human 
protein database version 3.37 was used which contains 69,289 proteins.  
Carbamidomethylation was set as fixed modification. As described above, MaxQuant 
classified SILAC partners according to labeling (i.e. light, medium, and heavy), and within 
each group the corresponding labeling was automatically set as fixed modification. 
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Variable modifications for proteome mapping dataset included oxidation (M), N-acetylation 
(protein), pyro (N-term QC). For phosphoproteome studies, variable modifications also 
include phospho(STY). Full tryptic specificity was required and up to three missed cleavages 
were allowed. Initial mass deviation of precursor ion and fragment ions were up to 10 ppm 
and 0.5 Da, respectively.  
The derived identification lists of peptides and their assigned proteins were further processed 
in Identify.exe. Posterior error probability (PEP) was calculated to estimate the chance of 
random peptide match for each spectrum, given the Mascot score and peptide length. False 
discovery rate (FDR) denotes the percentage of false identification hits in the entire dataset. 
To achieve highly reliable identifications, the following standard operating procedures (SOP) 
were employed:  
Proteome dataset: peptide PEP <=0.1, peptide FDR <=0.01, protein FDR <=0.01, peptide 
length >=6. To identify a protein, at least two peptides should be identified and one of them 
should be unique to this protein in the proteome. 
Phosphoproteome dataset: peptide PEP <=0.1, peptide FDR <=0.01, protein FDR <=1, 
peptide length >=6. Phosphorylation analysis is performed at the peptide level. 
 
3.4.2   Quantitation 
For quantitation, peptide ratios were calculated according to the intensities of all 2D centroids 
from each of the SILAC forms. Linear line fitting to these intensities gave the slope as the 
desired ratio. During this calculation, element enrichment in 13C, 15N due to the SILAC 
labeling were taken into account. To represent the ratio of a peptide being quantified several 
times, the median value was chosen. To minimize the effect of outliers, protein ratios were 
calculated as the median of all SILAC pair ratios that belong to peptides contained in this 
protein. Intensity based significance value was also calculated to estimate the degree of 
biological regulation. Complementary to this fine-tuning method, a threshold fulfilling 
stringent requirement such as 2-fold change (Ratio>=2 or Ratio<=0.5) is also commonly used 
to derive biological regulation. The latter was applied in all the projects in this thesis.  
 
Materials and Methods 
52 
 
3.4.3   Assign localization of the phosphate group  
For each possible phosphorylation site, the localization post-translational modification (PTM) 
score was calculated by matching the observed b and y ions with the theoretical b and y ions31. 
Results are displayed in MaxQuant output tables. To accurately assign the phosphorylation 
sites, two processing steps were performed: entries with PTM scores that are lower than the 
maximum score minus five are ignored, and localization of PTM probabilities are required to 
be at least of 0.75.  
 
3.4.4   Phosphoproteomic dataset stored in PHOSIDA database 
All the phosphoproteomic datasets from project 1 and 2 are stored in the PHOSIDA database 
as a public resource. The data will become available along with the publications. PHOSIDA 
routinely performs motif check (see section 3.5.2), structural analysis (see section 3.5.3), 
phosphorylation site prediction (see section 3.5.4), and evolutionary comparison181.  
 
 
3.5 Bioinformatic analysis 
3.5.1   Gene Ontology and KEGG enrichment analysis  
Routine GO analysis 
Cytoscape along with its Plug-in Bingo 2.0182 was used to analyze the distribution of 
experimental datasets among various protein groups, and to identify significantly 
overrepresented biological functions of the proteins. 
The Gene Ontology (GO) annotations of proteins were compared with the ones of a reference 
proteome (e.g. identified proteins vs. the entire protein database, or a subset of the identified 
proteins vs. the overall identified proteins). To assign corresponding GO identifiers to each 
IPI entry, the Gene Ontology Annotation database was used. The hypergeometric test and the 
Benjamini & Hochberg False Discovery Rate correction were performed to derive 
overrepresented functions 182. A probability value of 0.05 was considered significant. 
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Enrichment analysis based hierarchical clustering 
In project 3, Proteomic phenotyping to assess differences between transformed and non-
transformed mouse liver cells, the quantified proteome was divided into 5 quantiles 
corresponding to probability cutoffs of 0, 0.15, 0.25, 0.75, 0.85, and 1. The enrichment 
analysis for GO biological process and cellular component were done separately for these 
quantiles with respect to the whole quantified proteome by conditional hypergeometric test 
available in the GOstats package183 in the R statistical environment184. For hierarchical 
clustering we first collated all the categories obtained after enrichment along with their p-
values, and then filtered for those categories which were at least enriched in one of the 
quantiles with p-value < 0.05. This filtered p-value matrix was transformed by function x = –
log10 (p-value).  Finally these x values were transformed to z-score for each GO category by 
using the transformation: 
)(
)(
xsd
xmeanx −
.
 
These z-scores were then clustered by one-way hierarchical clustering using “Euclidean 
distance” as distance function and “Average Linkage clustering” method available in 
Genesis185. KEGG pathway enrichment analysis was done in the same way, except that the 
hypergeometric test was employed.  
 
3.5.2   Phosphorylation - motif check 
The known human kinase motifs were used to access the mouse phosphorylation dataset to 
identify possible matching kinase substrates181. χ2-Test was employed to perform the 
statistical evaluation. The applied χ2-Test checks whether the observed number of 
phosphosites that match with a given kinase motifs exceeds the number of expected sites to a 
statistically significant extent. To derive the number of expected motif matching phosphosites, 
the chance was estimated for each kinase motif to match with a given phosphosite according 
to the amino acid composition of the motif and the relative frequencies of each amino acid in 
the entire mouse proteome. This approach was applied to those phosphorylation sites that 
could be clearly assigned within the phosphorylated peptide sequence (class I sites). 
Furthermore, Motif-X186 was used to derive potentially new motifs in-silico and to confirm 
the observations of the χ2-Test. A probability value of 0.0001 was considered significant. In 
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addition, a minimum occurrence of 20 was required to derive a significant consensus 
sequence. This approach was performed residue-specific on all class I sites using the entire 
mouse proteome as a background model.  
 
3.5.3   Phosphorylation - structural analysis 
In order to check the structural constraints of phosphorylated residues in the mouse liver cells 
used in this thesis, the secondary structure and solvent accessibility prediction tool SABLE 
2.0181 was used. The predicted structural conditions of each phosphosite were stored in 
PHOSIDA.  
 
3.5.4   Phosphorylation - phosphorylation site predictor 
A support vector machine (SVM) was trained separately on unambiguously identified 
phosphorylation sites181. The essential feature of each phosphorylation site that was used as 
input for this machine learning approach was the raw sequence: the algorithm was mainly 
trained on the phosphorylated residue along with its surrounding sequence (+/- 6 residues). To 
generate a negative set of the same size, sites from mouse proteins that were not, to date, 
detected to be phosphorylated were randomly chosen. The positive and the negative datasets 
were split into a training set (90%) and a test set (10%). Parameters C and σ were then 
optimized by varying them from 2-10 to 210 in multiplicative steps of two on the basis of a 
five-fold cross validation on the training set. The optimal model for each set of each 
phosphorylated amino acid was obtained separately using the radial basis function (RBF). 
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4 Results and Discussions 
 
4.1   Project 1 - Quantitative phosphoproteome analysis of a liver cell 
line reveals specificity of phosphatase inhibitors 
 
This work is included in a manuscript that is accepted for publication:  
 
 
Phosphorylation is chemically stable under physiological conditions. However, enzyme-
catalyzed phosphorylation and dephosphorylation can occur at ice-temperatures and in 
disrupted cells, e.g. cell lysates. Chemical compounds such as protease inhibitors and 
phosphatase inhibitors are added during sample preparation, to prevent loss of activity and 
dephosphorylation of the proteins ex vivo. Cell-permeable phosphatase inhibitors can also be 
used on living cells to non-specifically increase levels of phosphorylation, for example in 
phosphoproteomics. Some of these inhibitor compounds are known to target a broad spectrum 
of phosphatases. Here we wanted to use these broadband phosphatase inhibitors to measure 
and quantify a mouse liver cell line (Hepa1-6) phosphoproteome in greatest depth. 
Additionally, the strategy of metabolically labeling the Hepa1-6 using SILAC enabled us to 
compare the specificity of these phosphatase inhibitor compounds. This can be achieved by 
comparing the number of regulated tyrosine phosphorylation sites and the number of 
regulated Ser/Thr phosphorylation sites against the overall identified phosphoproteome. 
Quantitative phosphoproteome analysis of a liver cell line reveals specificity of 
phosphatase inhibitors 
Cuiping Pan, Florian Gnad, Jesper V. Olsen and Matthias Mann  
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Furthermore, by introducing a biological stimulus into an additional SILAC state we were 
able to determine an upper limit to the stoichiometry of phosphorylation sites. 
The following three inhibitor compounds were used in this study. Sodium-pervanadate 
(Figure 4.1.1 A) is a broadband inhibitor for protein tyrosine phosphatases (PTPs). Calyculin 
A (Figure 4.1.1 B) targets PP1 and PP2A, the two largest groups of the serine and threonine 
phosphatase superfamily. Deltamethrin targets PP2B phosphatases.  
 
 
Figure 4.1.1   Chemical structures of phosphatase inhibitors. Panel A displays the 
monoperoxo from of pervanadate in comparison to the phosphate group and vanadate. Panel 
B displays the chemical structure of calyculin A.  
 
Pervanadate is a general term for various reaction products of hydrogen peroxide and 
orthovanadate. These peroxovanadium compounds are general PTP inhibitors. Though analog 
to phosphate group, their mechanism of inhibition is not simply as competitor with phosphate, 
but rather it is suggested that they oxidize the catalytic cysteine residue in the PTPs187. 
Calyculin A is a natural product isolated from marine sponge. It possesses a spiro ketal 
skeleton. Although its exact mechanism of action is not clear, it has been demonstrated to be 
highly potent in inhibiting pSer/Thr phosphatases 188, 189. Deltamethrin, a pyrethroid ester 
insecticide, has proven to be a specific inhibitor for PP2B190. All these three selected inhibitors 
are membrane permeable and therefore suitable for intact cell treatment.  
We employed SILAC-based phosphoproteomics strategy in this study (Figure 4.1.2). One cell 
population was labeled with normal (‘light’) arginine and lysine and another cell population 
with ‘heavy’ 13C615N4-arginine and 13C615N2-lysine (Arg10 and Lys8). After complete 
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incorporation, the heavy labeled cells were treated for 10 minutes with a mix of the three 
commonly used phosphatase inhibitors: 100 nM calyculin A, 0.5 mM pervanadate and 10 µM 
deltamethrin, in order to block phosphatases as broadly as possible. We lysed treated and 
control cells, precipitated proteins, mixed them in a one to one ratio and enzymatically 
digested the resulting 20 mg protein mixtures. Peptides were separated by strong cation 
exchange (SCX) and the resulting fractions enriched for phosphopeptides using TiO2 beads in 
the presence of DHB (section 3.3.1). Phosphopeptides were analyzed by high resolution mass 
spectrometry on a linear ion trap Fourier Transform instrument (LTQ-FT), using multistage 
activation. In all, 16 LC MS/MS runs were performed, using conditions described in section 
3.3.2. Data was analyzed as described in section 3.4, requiring a False Discovery Rate (FDR) 
for phosphopeptide identification of less than 1%. 
 
 
 
 
Figure 4.1.2   The strategy of SILAC-based quantitative phosphoproteomics to elucidate the 
efficiency of broadband phosphatase inhibitors in retaining phosphorylation.  
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4.1.1   Evaluation of the phosphoproteomics technique 
Crude fractionation of phosphopeptides by SCX 
 
Figure 4.1.3   Phosphopeptide elution profile of SCX. X-axis represents time and y-axis 
represents UV absorbance at 225 nm (magenta). The green curve indicates salt concentration. 
It directly correlates with the conductivity curve marked in brown. The blue curve displays 
UV absorbance at 280 nm. Other parameters are written at the top. Note the fraction numbers 
are adjacent to the x-axis, namely A1 to B15.. 
 
A total of 20 mg of tryptic peptides were divided into four equal units and fractionated by 
SCX separately. The resulting fractions were combined correspondingly. In each round of 
sample loading, liquids which did not bind to the column (“flow through” fraction) were 
collected. The peptides that bound to the column were eluted by linearly increasing salt 
concentration. All four elution profiles were very similar. One of them is shown in Figure 
4.1.3. Generally the elution profile is not sharp, suggesting that only a crude fractionation is 
achieved. UV absorbance indicates significantly fewer peptides at the late phase of elution 
(fraction A11-B15).  
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The efficiency of phosphopeptide enrichment by TiO2 spheres 
 
Figure 4.1.4   Phosphopeptide enrichment efficiency of TiO2 sphere. SCX fractions are 
marked in x-axis. Y-axis presents the number of peptide identification. On top of each column 
pair marks the enrichment efficiency, which was obtained by dividing the number of 
phosphopeptides by all peptides being identified in that fraction(s). Calculation is based on 
evidence.txt output from MaxQuant. 
 
The resulting fractions from SCX (Figure 4.1.3) were incubated with TiO2 sphere for 
phosphopeptide enrichment. The early fractions and the late fractions were combined before 
incubation. The flow-through fraction, which contained mainly multiple phosphorylated 
peptides, as well as the pellet sample from the cell harvesting step (section 3.1.5) were also 
incubated with TiO2. Because we estimated that the flow-through fraction might contain a rich 
amount of phosphopeptides, six times of TiO2 enrichment were performed in sequence.  
The enrichment worked well, with an overall efficiency of 0.85, defined as the fraction of 
phosphopeptides to all peptides: 100% enrichment efficiency gives the number of 1. The 
enrichment efficiency is displayed in Figure 4.1.4. Out of 17 samples, six samples achieved an 
efficiency equal to or above 0.95. It is noteworthy that the flow-through and pellet samples 
contained many more phosphopeptides than the SCX fractions, indicating that a large portion 
of the peptides did not bind to the SCX column. In fact, the six flow-through samples 
contributed 37% of overall identified non-redundant phosphopeptides (1,996 out of 5,457). 
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Further investigation revealed a significant overlap between adjacent flow-through samples. 
Interestingly, the first two of them constituted 1,222 phosphopeptides, 61% of those identified 
in all the combined six flow-through samples. The number of additional identified 
phosphopeptides levels off with sequential TiO2 enrichment (Figure 4.1.5). This could be 
caused by abundant phosphopeptides saturating the beads or less likely that we ready 
exhaustively recovered all phosphopeptides from these hepatocytes. Therefore further 
fractionation on the SCX flow-through sample should effectively enlarge the identification 
numbers. A promising method to do this would be strong anion exchange but this was not 
pursued here to keep the number of fractions to be analyzed manageable. 
 
 
Figure 4.1.5   Phosphopeptide identifications in flow-through samples. Calculation is based on 
non-redundant phosphopeptides.  
 
HPLC chromatogram 
Depicted in Figure 4.1.6 are two HPLC chromatograms from one SCX fraction and one flow-
through fraction. DHB introduced chemical noise into the mass spectra. The disturbance is 
obvious during sample loading, i.e. the first 22 minutes. However, when phosphopeptides 
started to elute their signal ‘suppressed’ the chemical noise.  
Phosphopeptides are typically of low abundance. In our mass spectrometric data, SCX 
fractions derived from 20 mg starting material typically required around 150 ms fill time in 
each survey scan to fill the trap with one million ions. Due to higher phosphopeptide 
abundance, the typical ion fill time of the flow through fraction from SCX loading was only 
50 ms. 
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Figure 4.1.6   HPLC elution profiles of a complex phosphopeptide mixture. 
 
Mass spectra: accurately pinpointing the localization of the phosphate group 
Phosphopeptide identification was performed with the software MaxQuant. Three MS/MS 
spectra are shown as examples in Figure 4.1.7 to Figure 4.1.9.  
 
 
Figure 4.1.7   MS/MS spectrum to identify the pSer 668 in DNA replication licensing factor 
MCM3. The b5-H3PO4, b6-H3PO4, y13- H3PO4 and y14- H3PO4 fragments clearly pinpoint the 
location of phosphate group to S668. 
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Figure 4.1.8   MS/MS spectrum to identify the pThr 267 in microfibrillar-associated protein 1. 
The b10-H3PO4, y14-H3PO4 and y15-H3PO4 fragments clearly pinpoint the location of phosphate 
group in T267 but not another serine or tyrosine residue. 
 
 
 
Figure 4.1.9   MS/MS spectrum to identify the pTyr 427 in SHC-transforming protein 1. The 
abundant y7 and y9 ions strongly indicate that the phosphate group locates to the tyrosine 
residue but not the serine residue. 
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4.1.2   Phosphoproteome of the mouse liver cell line Hepa1-6 
4.1.2.1   Overall identified phosphorylation sites and their distributions 
The combination of phosphatase inhibitor compounds in this experiment was close to the 
maximum dose and duration tolerated before cells started to detach and show signs of 
apoptosis. Normally growing cells do not significantly phosphorylate many of the important 
substrates that are phosphorylated in specific situations, such as after a given stimulus or at a 
specific point in the cell cycle. Phosphatase inhibitor treatment may enhance these 
phosphorylation sites and thereby make them analyzable by MS. In this way we could 
characterize the phosphoproteome in greater depth. Also, this quantitative strategy allows us 
to determine if the peptide is present – at least in a small amount – in normal cells, i.e. without 
phosphatase inhibitor treatment.  
A total of 1,808 phosphoproteins, 3,430 phosphopeptides, and 4,253 Class I phosphorylation 
sites were sequenced and identified. The majority of phosphopeptides were singly 
phosphorylated (75%), but a substantial fraction were either doubly (20%), triply (4%), or 
more highly (1%) phosphorylated (Figure 4.1.10 A). The distribution between 
phosphotyrosine (pTyr), phosphothreonine (pThr) and phosphoserine (pSer) was close to that 
observed in another large-scale phosphoproteomics study of human epithelial cells (HeLa) 
(Figure 4.1.10 B)31.   
 
 
Figure 4.1.10   (A) distribution of mono- and multiple phosphorylated peptides. (B) 
Frequency of class I sites, which are sites with the highest localization probability. 
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4.1.2.2   Characterization of the phosphoproteome of a mouse live cell line 
 
The phosphoproteome is distributed among diverse protein classes, functions and subcellular 
locations.  
Gene Ontology (GO) analysis assigned the phosphoproteome to cellular components, 
biological process and molecular functions (Figure 4.1.11). Given the fact that 
phosphorylation is involved in various cellular events, it is not surprising that these 
phosphoproteins are distributed among many different categories and functions. There are a 
large number of regulatory proteins in the phosphoproteome – for example 51 phosphorylated 
transcription factors and 121 phosphorylated protein kinases and 28 phosphatases.  
 
The phosphoproteome is overrepresented in protein binding and underrepresented in 
mitochondrial and secreted functions.   
In GO, we next analyzed which protein functions are overrepresented in the detected 
phosphoproteome compared to the entire mouse protein database. The results indicated that 
the most significantly overrepresented biological functions of phosphorylated proteins are 
associated with binding to targets ranging from transcription factors to ATP. Kinase binding 
activity, for example, is significantly overrepresented (p= 8*10-7). Functions that are related to 
general kinase activities, translational activation, and transcriptional regulation also proved to 
be significant. Conversely, mitochondria and secreted proteins were significantly 
underrepresented in the phosphoproteome similar to what we had already seen in the HeLa 
phosphoproteome 31. 
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Figure 4.1.11   Overview of the proteins categories found in the phosphoproteome. Some 
regulatory protein classes such as protein binding, kinase activities, as well as transcriptional 
and translational regulations are strongly represented. Analysis was performed using Gene 
Ontology (GO). 
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Phosphorylation largely localized to coil regions of protein surfaces.  
The solvent accessibility and secondary structure prediction by the bioinformatic software 
SABLE 2.0 revealed that the predominant localization of mouse phosphosites is in coil 
regions on the protein surfaces (Figure 4.1.12). This result is in concordance with the previous 
observation on structural constraints of phosphosites in the human proteome181. 
 
 
Figure 4.1.12   (A) Average solvent accessibility of phosphorylated residues is significantly 
higher than that of non-phosphorylated residues. The relative accessibility prediction assigns a 
value between 0 (fully buried) and 9 (fully exposed) to each residue. (B) Phosphorylated 
residues are more frequently located in loops and coils than the non-phosphorylated residues. 
Calculations were performed in SABLE 2.0. Blue: phosphorylated residue; red: non-
phosphorylated residue. 
 
 
Overlap between the mouse live cell line phosphoproteome and SwissProt phosphorylated 
proteins.  
In this experiment, 1,033 phosphorylated proteins were identified that contain class I 
phosphorylation sites and have a corresponding SwissProt accession numbers. The current 
SwissProt release (54.7) reports 3401 proteins that are phosphorylated in mouse, disregarding 
method of experimental detection and including computational prediction by similarity. In 
total, 864 proteins overlapped between these two datasets (Figure 4.1.13). This is a striking 
overlap, given that there are more than 50,000 protein entries in the mouse IPI database. This 
observation implies that the core phosphoproteome, at least at the level probed here, is quite 
well conserved between different mammalian cell types and tissues. However, at the 
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phosphosite level, our dataset has substantial novelty as more than half (1,428) of 2,590 class 
I sites, whose assigned proteins show SwissProt accession numbers, is novel compared to 
what is currently recorded in SwissProt. In total, SwissProt contains 11,304 residues that are 
phosphorylated on mouse proteins. 
 
 
Figure 4.1.13   Overlap of phosphorylation sites found in this study with phosphorylation sites 
in the SwissProt database.  
 
Overlap between the mouse live cell line phosphoproteome and mouse liver tissue 
phosphoproteome.  
We were also interested in determining the overlap in phosphorylation sites between our liver 
cell line and liver tissue. Gygi and coworkers recently published a large-scale study of the 
mouse liver phosphoproteome which contains over 5,600 phosphorylation sites191. We 
extracted those phosphorylation sites and compared them to our dataset. Interestingly, this 
overlap was much smaller than the overlap with the phosphorylation sites in SwissProt. About 
half of our phosphoproteins were also detected in the tissue study, and about 30% of the 
phosphorylation sites on those proteins were identical. At this point, it is difficult to assess 
whether this discrepancy is due to differences between cell lines and tissues, or due to 
technical factors – both studies identified roughly equally large proteomes but neither is 
exhaustive.   
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Consensus sequences (motif) of kinase substrates. 
 Each of the phosphorylation sites identified in our dataset is the substrate of one or more 
kinases. Through motif analysis we matched our sites to the known substrate specificities of 
33 human kinases. We used the published human kinase motifs (www.phosida.com) because 
the mouse ones are not known and kinase substrates are generally assumed to be well 
conserved between human and mouse. For each kinase motif, we determined the number of 
phosphorylation sites that matched the pattern, the number of sites expected to match this 
pattern by chance and the statistical significance of any overrepresentation using the χ2-test. 
The main finding of the consensus sequence analysis is that phosphorylation sites of the 
mouse proteome match significantly with specified human kinase motifs with only a few 
exceptions such as the motif of the NEK6 kinase (Appendix 2). The number of phosphosites 
that match with given motifs of the protein kinase A (PKA) is ten times higher than one 
would expect by chance, for example. These results were confirmed by the Motif-X algorithm 
186
 (Appendix 3). 
 
4.1.2.3   Assessment of our phosphoproteomics technology 
 
More than three orders of magnitude in phosphopeptide intensities.  
To our knowledge the dynamic range of phosphopeptide detection has not been described 
before. We determined the apex of the intensity over the LC MS peak for the isotope cluster 
of each phosphopeptide. Figure 4.1.14 shows that the identified phosphopeptides follow a 
Gaussian intensity distribution on a logarithmic x-axis, which spans between three to four 
orders of magnitude. This is the same dynamic range than that of unmodified peptide 
detection on our LTQ-FT instrument131, and for the LTQ-Orbitrap192 and probably reflects 
technical rather than biological properties.   
Also indicated in the figure is the distribution after phosphatase inhibitor treatment. This 
curve is shifted by about a factor two relative to the untreated population, indicating that 
identification of lower abundance phosphopeptides from untreated cells was indeed enabled 
by this phosphatase strategy. This trend is especially striking at the left side of the graph, 
where the abundance bins contain very few ‘heavy labeled’ peptides. These ‘light’ 
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phosphopeptides were only identified because of their more abundant, SILAC-counterparts 
that had been phosphatase inhibitor stimulated.  
 
 
Figure 4.1.14   Number of phosphopeptides in different intensity bins. Just like the proteome, 
the phosphoproteome follows a roughly Gaussian distribution on a logarithmic scale. The 
light shaded bars represent the phosphopeptides from the light labeled SILAC cells (untreated) 
and the black bars the phosphopeptides from the heavy labeled SILAC cells (phosphatase 
inhibitor treated).  
 
Phosphorylation correlates with protein abundance.  
We next compared the abundance of the phosphoproteome of 1,808 proteins to the abundance 
of the proteome of the same cell type (data from Project 3). The proteome (4,089 proteins) 
was binned into abundance classes by means of the added peptide intensities (Figure 4.1.15 
A). We then binned the phosphoproteins into the same abundance classes (Figure 4.1.15 B). 
Comparison of panels A and B reveals that the phosphoproteome roughly follows the 
abundance curve of the proteome, suggesting that to some degree phosphorylation occurs 
evenly among proteins without bias with respect to abundance. Thus, hyper-phosphorylation 
on low abundant proteins, or hypo-phosphorylation on high abundant proteins seemingly is 
not the general phenomena in cells. This comparison also suggests that we are not 
substantially biased against low abundance proteins – at least not compared to a proteome 
analysis.  
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Figure 4.1.15   Proteome and phosphoproteome abundance. (A) Abundance of 4,089 proteins 
in the Hepa1-6 proteome (data from project 3). (B) Percentage of proteins in (A) for which at 
least one phosphorylation site was detected. Note that the left hand tail in this curve is 
depressed even though phosphoproteome measurement enriches for low abundance proteins. 
This is caused by the fact that the chance to detect the corresponding protein in a proteome 
measurement for a low abundance phosphopeptide is small.  
 
4.1.3   Effects of calyculin A, deltamethrin, and pervanadate  
4.1.3.1   Regulation of phosphopeptides by the inhibitor compound mixtures 
We next asked how many phosphopeptides showed a fold-change due to the phosphatase 
inhibitor treatment (Table 4.1.1). Surprisingly, only 27% of the peptides were induced more 
than two-fold by this treatment. Note that some phosphorylation sites (8%) decreased instead 
of increased after phosphatase inhibitor treatment. This is due to the fact that phosphorylation 
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can both activate and deactivate target proteins and its downstream signaling cascade. For 
example, dephosphorylation in glycogen synthase is required for its activation. 
 
 
 
Table 4.1.1   Overall regulation by phosphatase inhibitors. The star (*) indicates that the total 
number of phosphopeptides is calculated by separately summing up all detected phospho-
states for the same peptide. 
 
 
4.1.3.2   Overall regulation of the inhibitor compound mixtures 
As noted, not all phosphosites were equally affected by phosphatase inhibitors. We plotted the 
fold-change of phosphorylation sites for each amino acid separately in Figure 4.1.16. As 
tyrosine phosphorylation is much less abundant compared to serine and threonine 
phosphorylations, we performed immunoprecipitation (IP) to enrich pTyr containing peptides 
using 4G10, a pTyr specific antibody, and obtain 480 pTyr sites (section 4.1.4). The data 
displayed in Figure 4.1.16 A come from this 4G10 IP experiment.  
It is immediately apparent from the figure that tyrosine phosphorylation sites are dramatically 
affected by phosphatase inhibitor, while this is much less the case for serine/threonine. For 
pTyr, the majority of sites are up-regulated at least two-fold (70%). This is presumably due to 
the broad effect of pervanadate on all PTPs combined with the low level of tyrosine 
phosphorylation in untreated resting cells. For phosphothreonine only 41% of the sites were 
up-regulated at least two-fold and for phosphoserine the number is only 26%. This is a 
surprisingly low number considering that the inhibitors we used are generally employed in 
cell biology, and are usually thought to block most phosphatase activity.  
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Figure 4.1.16   Phosphatase inhibitors displayed specificity. Percentage of phosphopeptides 
as a function of up-regulation due to inhibitors.  (A) Most of the phosphotyrosine peptides are 
regulated several fold due to pervanadate treatment. (B) and (C), A proportion, but not all, 
phosphothreonine  and phosphoserine peptides are affected by the treatment of Calyculine A 
and deltamethrine.  
 
4.1.4   Estimating an upper bound on the stoichiometry of phosphorylation 
Quantitative phosphoproteomics, as done with SILAC, compares the relative levels of 
phosphorylation between two cellular states. However, it is frequently also important to know 
the degree of phosphorylation or ‘occupancy’ of a given phosphorylation site. There are few 
available strategies to measure occupancy, particularly in large-scale experiments and they 
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usually involve the use of isotope labeled synthetic peptides193 or require the observation of 
both the unphosphorylated and the phosphorylated form of the peptide194. 
The work of Erba et.al195 addressed the concept of using a phosphatase inhibitor to detect 
phosphorylation occupancy. Several tyrosine phosphorylation sites on EGFR upon EGF 
stimulation were quantified. By using sodium-pervanadate-induced super-physiological 
phosphorylation as a reference, the occupancies of the EGF-induced phosphorylation of these 
tyrosine sites were calculated. However, the endogenous phosphorylation state of these 
tyrosine sites were not considered, therefore one cannot necessarily conclude that these 
occupancy rates were induced by EGF treatment. For complete information one also has to 
include the basic phosphorylation state.  
Therefore we chose to include an additional SILAC state. Three cell populations are 
differentially labeled by SILAC. The light labeled cells serve as control, the medium labeled 
cells are treated with the stimulus of interest, e.g. a growth factor, and the heavy labeled cells 
are treated with the phosphatase inhibitor cocktail. The expected pattern of regulated 
phosphosites is less phosphorylated in the control cells and more phosphorylated in the 
phosphatase inhibitor treated cells, with the growth factor simulated cells somewhere in 
between. Importantly, the stoichiometry of phosphorylation after stimulation cannot be higher 
than the ratio between the heavy and medium labeled forms of the phosphopeptide.  
 
Insulin-induced phosphorylation occupancy 
We investigated the phosphorylation occupancy upon insulin stimulation in these mouse liver 
cells (Figure 4.1.17). We treated triply encoded SILAC liver cells with no stimulus, 5 minutes 
stimulation with 100 nM insulin, and phosphatase inhibitors (section 3.1.5). In order to obtain 
a larger number of pTyr sites, we employed a separate tyrosine enrichment step in our 
experimental protocol. After immunoprecipitation with the pTyr specific antibody 4G10, we 
quantified a total of 480 pTyr sites in this liver cell line.  
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Figure 4.1.17   Experimental design for the phosphorylation site experiment to determine an 
upper limit of stoichiometry. (A) Cells are triple SILAC labeled. One population serves as 
control, one is stimulated with insulin and one is treated with phosphatase inhibitor.   
 
As shown in Figure 4.1.18, insulin induced the phosphorylation site of Y1175 in the 
activation loop of the mouse insulin receptor by more than ten-fold compared to control cells. 
The phosphopeptide ratio between insulin stimulated and phosphatase treated cells is 1.75. 
Since a given phosphorylation site cannot be occupied more than 100%, this data puts an 
upper limit on this phosphorylation site of 60% after 5 minutes insulin stimulation. Figure 
4.1.18 also shows the example of a serine phosphorylation site, which is up-regulated 
compared to basal condition by a factor 2.4. From this it follows that occupancy cannot be 
greater than 24% under the given condition.  
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Figure 4.1.18   Examples of peptides with unchanging phosphoprofile and peptides that are 
phosphorylated in response to insulin and even more increased in response to phosphatase 
inhibitors.  
 
We have found this method to work more generally for tyrosine phosphorylation than for 
serine/threonine phosphorylation, because the latter are less induced by the inhibitors (section 
4.1.3.2).  
 
4.1.5   Conclusions and discussions 
In this project we employed a mixture of three broadband phosphatase inhibitor compounds to 
boost phosphorylation in live cells. This approach enabled us to determine the 
phosphoproteome of mouse liver cell line Hepa1-6 in great depth. Phosphorylation is essential 
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for many cellular processes and malfunction of kinases and phosphatases are often found in 
cancer. There is no doubt that knowledge of complete phosphoproteomes will greatly 
facilitate our understanding of fundamental biological principles as well as disease 
developments at a systematic level. It may even provide guidance to developing therapies and 
drugs. 
In our study, a large Hepa1-6 phosphoproteome containing 4,253 accurately assigned 
phosphorylation sites was derived. General features of the phosphoproteome are similar to 
what our laboratory reported in a recent large-scale study of human HeLa cells31. Interestingly, 
the phosphoproteome is highly enriched for protein binding functions and interaction domains. 
This is readily understandable in terms of the signaling functions of this modification. 
However, this finding also implies that a significant proportion of the phosphoproteome 
measured here is indeed functional rather than being phosphorylated through an ‘innocent 
bystander’ effect. If this was not the case, we would have expected preferential ‘background’ 
phosphorylation of the most abundant proteins, i.e. metabolic enzymes and the like.  
For the first time in the phosphoproteomic field, we have assessed the dynamic range of 
phosphopeptide detection, which turned out to be up to four orders of magnitude with our 
current technology.  
We found quite good overlap with phosphorylation sites recorded in SwissProt, but more than 
half of the sites found here are nevertheless novel. This suggests that phosphoproteomic is not 
close to ‘saturation’ yet.  
We employed SILAC for quantitation of the phosphoproteome. Here we used the SILAC 
technology to quantify basal phosphorylation against the degree of phosphorylation after 
applying a cocktail of phosphatase inhibitors. For phosphotyrosine, inhibition was effective 
and the majority of pTyr sites were strongly increased upon treatment. For phosphothreonine, 
and even more for phosphoserine, a majority of sites was unaffected by the inhibitors. This 
was not due to unusually low doses as our protocol is within the range commonly used in the 
literature and as cells began to detach after phosphatase treatment. There are several 
possibilities that could explain the lack of universal up-regulation of pThr/pSer sites. The 
inhibitors could be specific for only some classes of phosphatases and leave others active. 
Alternatively, cellular kinase could have a small rate of phosphorylation for a majority of 
phosphorylation sites. Thus inactivation of phosphatases would not be noticeable for those 
sites. It would be interesting to follow up on the observations made here by testing panels of 
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phosphatase inhibitors separately, at different doses and for different times. Regardless of the 
outcome of such studies, we conclude that broad action and non-specific of serine/threonine 
phosphatase inhibitors cannot be taken for granted.  
The methods applied here are completely generic and could also be used in the same way for 
testing the specificity of phosphatase inhibitors in development as drugs.  
We also introduced several novel analytical concepts in this project. First, we employed 
phosphatase inhibitors to boost low level phosphorylation sites and make them more likely to 
be sequenced and identified. Importantly, the presence of the SILAC partner peptide from the 
unstimulated cells ensures that the phosphorylation site in question is endogenous and not an 
artifact of the inhibitor. Secondly, we devised a method to put an upper bound on the 
stoichiometry of sites that are heavily regulated by phosphatase inhibitor relative to control 
(as shown for insulin regulated sites). As demonstrated here, phosphoproteomics is fast 
becoming a very streamlined technology that can be used in many different ways to 
characterize signaling pathways and help in drug development.  
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4.2 Project 2 - Global effects of kinase inhibitors on signaling 
networks revealed by quantitative phosphoproteomics 
 
This work is included in a manuscript in preparation:  
 
 
Phosphorylation regulates a vast number of cellular processes and is of pivotal importance in 
signal transduction. Abnormal phosphorylation is found in various diseases, especially in 
cancers, where kinase aberration (usually secondary to genetic alterations) is often critical for 
their etiology and pathology54. For this reason much effort has been devoted to understanding 
kinase function and to manipulating their actions. One widely adopted strategy is to suppress 
kinase activity by small molecule inhibitors. While chemical inhibitors have been used in 
laboratory research for decades, the concept of specific kinase inhibitor drugs was only 
established in recent years. Today, kinase inhibitor compounds amount to about 30% of dug 
development programs in the pharmaceutical industry196.  
Techniques to measure inhibitor effects were only established in a high throughput manner in 
the last ten to twenty years. Conventionally interactions between the inhibitor compound and 
a panel of selected kinases are profiled in vitro71, 197. When systematic screening methods are 
introduced, these enzyme assays can include more kinases and cover the kinome more broadly. 
As a result, tests that are less biased can be performed. Examples of these advanced methods 
include phage plaque assays combined with quantitative PCR198, yeast three-hybrid199, and 
mass spectrometry with affinity chromatography200, 201. While these in vitro studies greatly 
help in defining the targets of kinase inhibitors, they have several limitations. Chemical or 
genetic modifications are often required, such as fusing kinases with bacterial phage proteins 
in phage plaque assays, with linker proteins in the yeast three-hybrid approach or addition of 
Global effects of kinase inhibitors on signaling networks revealed by quantitative 
phosphoproteomics  
Cuiping Pan et al. 
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chemical linkers to inhibitor compounds in affinity chromatography purification. These 
manipulations are often laborious and time-consuming. Besides they risk changing the 
properties of kinases and inhibitor compounds. Furthermore, these methods can only address 
the direct targets of the inhibitor compounds but not their influence on the cellular signaling 
network in total. For example, the same kinases can be employed by multiple signaling 
pathways, thus their functions on downstream signaling events can be difficult to predict. This 
complexity complicates the picture and therefore it is difficult to estimate or predict the 
overall effects of inhibitor compounds in a cellular environment. Certainly a cell-based 
approach, which allows system-wide elucidation of the effects of kinase inhibitors, will 
further improve the target evaluation process.  
While cell imaging provides direct visualization of the kinase inhibition effects in vivo202-205, 
cell system based quantitative mass spectrometry is able to simultaneously monitor protein 
expression and modification events at a much broader scale. Stable-isotope labeling by amino 
acids in cell culture (SILAC), a metabolic labeling method applied during cell growth, 
generates completely stable isotope labeled cell populations that are otherwise equal to non-
labeled cells. This system enables a direct comparison of several cell populations with 
different biological or chemical treatments. For example, when SILAC was applied to study 
the effect of the Her2 kinase inhibitor, cellular changes of tyrosine phosphorylated proteins 
due to this treatment could be quantified206. 
In recent years, studies of phosphorylation have been greatly enhanced by progresses in mass 
spectrometric techniques. Significantly, phosphopeptide enriching methods such as IMAC 
and titanium sphere chromatography have demonstrated detection of thousands of 
phosphorylation sites, completely changing the capabilities of the phosphoproteomics field28, 
94-97
. We reasoned that the combination of SILAC and the most recent phosphoproteomics 
technique should provide a powerful tool to explore the effects of kinase inhibitors on the 
overall cellular signaling network. This could help translating our knowledge of kinase 
inhibitor effects from the unit of individual proteins to the level of the whole (phospho)-
proteome. Furthermore, modern phosphoproteomics makes it possible to identify and quantify 
individual phosphorylation sites. As multiple phosphorylation sites on the same protein can 
have different functions and can be regulated differently, this detailed information can 
precisely pinpoint the responsive sites and provide a much more detailed picture of the 
inhibitor effects.  
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As proof of principle, we first examined two widely used inhibitor compounds in signal 
transduction laboratories: U0126 as a MEK1/2 inhibitor and SB202190 as a p38α/β inhibitor. 
Next, we applied the same technique to screen the effects of dasatinib, a clinical drug used to 
inhibit mutated BCR-ABL in chronic myelogenous leukemia (CML). 
 
4.2.1   Effects of U0126 andSB202190 on the EGFR signaling pathway 
U0126 and SB202190 are very potent, cell-permeable inhibitors for MEK1/2 and p38α/β, 
respectively. Their corresponding IC50 values are at the sub-micromole range. Previous 
studies characterized both as highly selective inhibitor compounds71, 198. However due to their 
pharmacological limitations, neither of the two inhibitors entered clinical trials but they are 
instead used as research compounds in laboratories. Thousands of publications employed 
these compounds and various kinase functions have been derived.  
SB202190 is a pyridinyl imidazole (Figure 4.2.1). It binds to the ATP pocket of p38α/β, and 
therefore precludes ATP binding to the kinase. Since ATP pockets are conserved among 
kinases, it is suggested that the specificity of the inhibitor compound is largely achieved by 
utilizing other residues than the direct ATP binding sites. A likely additional interaction site 
on the inhibitor is the 4-phenyl ring 54, 207.   
 
 
Figure 4.2.1   Chemical structure of SB202190, a p38α/β MAPK inhibitor. Its chemical name 
is 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole, with the molecular 
formula: C20H14FN3O. Molecular mass is 331.34 g/mol. 
 
Different from SB202190 and most other inhibitor compounds, U0126 (Figure 4.2.2) does not 
compete with ATP. Therefore the high ATP concentration in the intracellular milieu (2-10 
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mM) has only minimum influence and U0126 represents a unique group of kinase inhibitors. 
U0126 exerts its inhibitory effect mainly by binding to inactivated MEK1/2 and precludes 
allosteric change of the kinase domain. Therefore MEK1/2 are locked in their inactive 
confirmation71.   
 
Figure 4.2.2   Chemical structure of U0126, a MEK1/2 inhibitor. Its chemical name is 1,4-
diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene, with the molecular formula: 
C18H16N6S2. Molecular mass is 380.50 g/mol. 
 
MAPK family proteins propagate signals for various growth factors and inflammatory stimuli. 
MAPK signaling consists of several tiers: upstream signaling proteins such as growth factor 
receptors, MAP3Ks, MAP2Ks, MAPKs, and downstream proteins such as the ribosomal 
protein S6 kinase p90RSK. There are four major MAPK cascades: ERK1/2, ERK5, JNKs, and 
p38 MAPKs. These cascades are similar but can perform different cellular functions208, 209. To 
investigate their specific kinase functions it is important to have highly selective kinase 
inhibitor compounds. For example, to study ERK1/2-dependent cellular functions, U0126 and 
PD 98059 are often employed as ERK1/2 are generally considered as the highly dominant, if 
not the only, physiological target of MEK1/2 (also called MAP2K1/2). For elucidating the 
cellular functions of p38α/β, inhibitor compounds such as SB202190 and SB203580 are 
frequently applied.  
ERK1/2 and p38α/β can be activated by EGF in HeLa cells31. Based on this cell system, we 
examined the effect of SB202190 and U0126 on the overall signaling network. We set up 
three conditions in which HeLa cells were SILAC-labeled with distinct forms of arginine and 
lysine. Light labeled cells (Arg0, Lys0) remained untreated and served as control. Medium 
labeled cells (Arg6, Lys4) were stimulated with growth factor, whereas heavy labeled cells 
(Arg10, Lys8) were treated with both kinase inhibitor and growth factor stimulation (Figure 
4.2.3 A).  
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Figure 4.2.3   Strategy to detect the effects of kinase inhibitors on cellular signaling network.  
(A) Three SILAC-labeled cell populations are subjected to different treatments as indicated. 
(B) Principle response of the targeted kinase and its downstream substrates in the three 
SILAC conditions.  
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For the two inhibitor treatments a concentration of 10 µM was applied to heavy labeled cells 
for 20 minutes. In the presence of the inhibitor we applied 150 ng/ml of EGF to the cells for 
another 15 minutes. The medium labeled cells were treated with 150 ng/ml of EGF for 15 
minutes. Combined cell lysates from these three conditions were subjected to our 
phosphoproteomics processing workflow as described in section 3.3.  A simple diagram of the 
targeted kinase and their downstream substrates is displayed in Figure 4.2.3 B. 
 
4.2.1.1   Identification and quantitation results 
Mass spectrometric data from the two inhibitor experiments were processed and quantified 
with in-house developed software MaxQuant. Identification was performed by searching the 
IPI_human protein database using the Mascot algorithm. Statistical calculations are based on 
combined Mascot plus post-translational modification (PTM) scores. The following criteria 
have to be met for all included peptides: peptide posterior error probability (PEP) <=0.1, and 
peptide false discovery rate (FDR) <=0.01 (see section 3.4). Using the PTM score31, we could 
localize the phosphate groups with high confidence (Class I phosphosites) in 5,497 cases. A 
total of 5,748 phosphopeptides were quantified from 2,048 proteins. 
Quantitation results of experiments with both inhibitors are listed in Table 4.2.1. 
Phosphopeptides were grouped into three major categories based on their response to EGF, 
namely up-regulated (Ratio M/L>=2), down-regulated (Ratio M/L<=0.5), and non-changed 
(0.5<Ratio M/L<2). Within each category, phosphopeptides were further sorted according to 
their response to the kinase inhibitor. The majority of the phosphopeptides (~85%) were 
influenced by neither the growth factor nor the kinase inhibitors. Even though the overall 
numbers of quantified phosphopeptides are different in both experiments, the percentages of 
EGF up- and down-regulated phosphopeptides are similar, with ~10% upregulated and ~2% 
downregulated in each case. This indicates that the difference in overall phosphopeptide 
numbers is mainly due to technical factors. 
Not surprisingly, multiple phosphopeptides of the same protein can have different response 
patterns. A striking example is the neuroblast differentiation-associated protein AHNAK. 
Among 50 quantified phosphopeptides of AHNAK, six of the nine possible response patterns 
were found.    
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Table 4.2.1   Quantitation results of the U0126 and SB202190 experiments. 
 
M/L represents ratio of “medium labeled cells” (EGF stimulation) versus “light labeled cells” 
(inhibitor pretreatment and EGF stimulation). Within each category, ratios are further 
classified according to their responses to the inhibitor. Up-regulation: Ratio>=2.0; down-
regulation: Ratio<=0.5. 
 
 
4.2.1.2   Effects of the inhibitors on MEK1/2 and p38 α/β signaling branches 
 
Known and novel substrates of MEK1/2 and p38α/β 
Phosphorylation of the activation loop directly reflects kinase activity. We captured the 
relevant phosphopeptides from the activation loops of ERK1/2 and p38α in both experiments. 
In agreement with many other reports, they were highly induced by EGF but suppressed by 
their corresponding inhibitors without cross reaction (Figure 4.2.4). Several specific 
downstream targets of these inhibited kinases, such as Thr69/Thr71 in the transcription factor 
ATF2210 and Thr359/Ser363 in the kinase p90RSK211, displayed the same response patterns. 
Some phosphorylation sites of the upstream proteins were not affected. Examples include 
Ser991/Ser995 of the EGFR. 
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Figure 4.2.4   Effects of the inhibitors on known substrates of signaling branches of ERK1/2 
and p38 α/β.   
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In principle, downstream substrates of the targeted kinase should display the same response 
pattern as the kinase itself. However, a different response pattern can still be observed for the 
kinase downstream substrates if a phosphatase is involved or the signaling kinetics at later 
stages is considered (for example, the P9 pattern in Table 4.2.1). Phosphatases reverse 
phosphorylation and therefore decrease the intensity of phosphopeptides in MS. Under the 
specific EGF stimulation condition in this study, those late regulation events of 
phosphorylation may not have happened. To simplify further analysis, we will only consider 
those phosphopeptides with the same response pattern to the kinase (up upon EGF stimulation 
and down upon inhibitor treatment; P3 in Table 4.2.1) as potential direct or indirect 
downstream substrates. On this basis, there are 151 potential peptide substrates of MEK1/2, 
and 276 (excluding p38α/β) potential peptide substrates of p38α/β.There are 78 shared 
peptides between these two groups of potential kinase substrates. Analysis in Gene Ontology 
indicates that their corresponding proteins are involved in diverse biological processes but 
their molecular function is dominantly ‘binding’ (e.g. protein binding, nucleotide binding, and 
metal ion binding). 
 
Crosstalk between MEK1/2 and p38α/β signaling pathways 
To better define shared and specific substrates, we selected those peptides that were quantified 
in both inhibitor experiments. Again to simplify interpretation, EGF up-regulation 
(RatioM/L>=2) was set as a prerequisite. Phosphosites with accurate localization, i.e. class I 
sites, are classified into three groups (Figure 4.2.5 A): MEK1/2 specific (“U” group), p38 α/β 
specific (“S” group), and shared (“X” group) phosphosites.   
Proline at the +1 position following pSer/pThr is a well accepted kinase motif for MAPKs. 
Within each group we analyzed the adjacent amino acid residues surrounding each 
phosphorylation site.  Interestingly, the percentages of proline-directed phosphopeptides 
(pS/pT-P motif) are low, ranging from 15% to 30% (Figure 4.2.5 B). This indicates that the 
majority of these potential substrates are secondary or further downstream substrates of 
MEK1/2 and p38α/β. This is not unexpected, as MAP2Ks and MAPKs are generally located 
in a relatively upstream position in growth factor signaling pathways.  
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Figure 4.2.5   (A) Overlap between potential phosphosite substrates of MEK1/2 (Red circle) 
and p38α/β (blue circle). (B) Distribution of proline-directed and non-proline-directed 
phosphorylation sites. U (U0126) group - specific to MEK1/2, S (SB202190) group - specific 
to p38α/β, and X group - shared. 
 
Although ERK1/2 and p38α/β share 50% sequence similarity, they are employed in different 
cellular responses209. ERK1/2 are activated by various stimuli to regulate meiosis, mitosis, 
and postmitotic functions in differentiated cells. p38 MAPKs are strongly activated by 
cytokines and stress factors, including osmotic shock and heat shock, and to regulate immune 
and stress responses. The conserved motif in kinase activation loop is Thr-Glu-Tyr (TEY) for 
ERK1/2 and Thr-Gly-Tyr (TGY) for p38α/β. Previously, comparison of the substrates for 
ERK1/2 and p38α/β was reported at the transcription level212. Here we are able to compare 
their substrates at the phosphorylation level in the overall signaling network. Generally, 
phosphorylation involves rapid and short-term regulation events whereas transcription starts 
later, typically after 30 minutes. Our comparison is based on an active signaling network after 
15 minutes of EGF stimulation, where the signal was propagated to various downstream 
effectors and the forward signal dominated over the feedback signal. It is within this network 
that we discovered many differentially regulated phosphosites by MEK1/2 and p38α/β. These 
phosphosites come from important signaling proteins, such as JNK3, PLC, MSK2, HSP27, 
death-inducer obliterator 1, DNA topoisomerase 2-alpha, and so on.  
Requiring EGF up-regulation as a prerequisite, we have limited our analysis to a small, more 
easily analyzable dataset. Still, caution should be exercised in data interpretation. U0126 was 
previously reported to inhibit ERK5, a fourth family member of MAPKs besides ERK1/2, 
JNKs, and p38 MAPKs. ERK5 shares the same consensus motif TEY as ERK1/2. However, 
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ERK5 is unique in its carboxy-terminal half and possesses a nuclear translocation signal in its 
sequence. It is involved in cardiovascular development and neural differentiation208. Due to 
their distinctive features, the downstream substrates of ERK5 and ERK1/2 may be different. 
Suppressing both at the same time can cause ambiguity in assigning the structure of the 
network. From the perspective of drug effect screening, it is precisely the strength of our 
unbiased, systematic approach using quantitative MS that it provides a clear view of the 
overall effects of the inhibitor treatment.  
 
Evaluation of EGF signal propagation 
Based on the analysis of phosphorylation sites, we created a rough model of EGF signal 
propagation upon 15 minutes of 150ng/ml EGF stimulation (Figure 4.2.6).  
 
 
  
Figure 4.2.6   A simple model of EGF signal propagation. Overall 350 class I phosphosites 
were up-regulated by EGF in both inhibitor experiments. The percentages of proline-directed 
phosphorylation events are listed.  The three groups (U, X, and S) are the same as in Figure 
4.2.5.  
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Overall 350 class I phosphorylation sites were activated by EGF. Of these, 82% participated 
in MAPK cascades as judged by their suppression after MAPK inhibitor treatments, leaving 
only a small role for other signaling cascades. Within the MAPK cascades, the signal diverged 
to MEK1/2, p38α/β and other branches. The fraction of proline-directed peptide substrates is 
only 15 – 30%, indicating that the signal spreads from a limited set of direct substrates to a 
broad set of secondary and further downstream effectors. Although only a rough estimate, this 
model is very interesting in itself. It suggests that MAPK cascades are predominant in these 
growth factor induced signal transduction events. Again, it clearly demonstrates the strength 
of quantitative MS and systems biology approach in reconstructing the signaling network. 
 
4.2.1.3   Potential side effects of the inhibitor compounds  
Off-target effects are a major concern for inhibitor compound development. As most kinase 
inhibitors are ATP competitors and ATP binding pockets are conserved among kinases, it is 
likely that inhibitor compounds suppress more kinases than the targeted one. The fact that 
these suppressed kinases can have limited sequence homology further complicates analysis. 
Besides the off-target issue, there is an equally important question in the field, namely the 
secondary effect of the kinase inhibitor compound on the signaling pathway. This issue has 
been addressed to a lesser degree and in a less systematic manner due to the technical 
limitations. The strength of our approach is to examine the global effects of kinase inhibitors 
over the entire network. 
Previously we discussed the potential peptide substrates of MEK1/2 and p38α/β. Here we set 
out to inspect some other phosphorylation changes that can potentially introduce drastic 
effects into the signaling network. Phosphopeptides that were up-regulated by the inhibitor 
compounds compared to EGF only treatment (RatioH/M>=2) are at first unexpected and 
demonstrate the ability to distort EGF effects and therefore are of great interests.  
In the SB202190 dataset, 70 phosphopeptides fulfilled this criterion. Among the list are 
Tyr301 of A-Raf and three phosphosites (Thr58, Ser61, and Ser63) from PP2A regulatory 
subunit beta. A-Raf closely resembles Raf-1, a major signaling molecule of the EGF response, 
in sequence and activation mechanism. Ras-GTPase and Src can activate both Rafs by 
phosphorylating two adjacent tyrosine residues, Tyr-301/302 in A-Raf and Tyr-340/341 in 
Raf-1213. We detected reduced phosphorylation of Tyr301 in A-Raf upon EGF treatment 
(RatioM/L=0.5). However SB202190 treatment reversed this down-regulation (RatioH/M=9.5) 
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such that this phosphorylation site is now up-regulated instead. This suggests that the A-Raf 
signaling branch is greatly activated after the inhibitor treatment. The reversed 
phosphorylation of the regulatory subunit of phosphatase PP2A (RatioM/L=0.1, RatioH/M=8) 
likewise could induce a drastic change, given the fact that PP2A governs dephosphorylation 
events on various signaling molecules.  
Together, 50 phosphopeptides in the U0126 dataset display RatioH/M>=2. Interesting examples 
include the activation motif of JNKs (Thr221/Tyr223 with RatioM/L=2.6, RatioH/M=6.5), IRS-2 
(Ser596 with RatioM/L=1.1, RatioH/M=2.2), and HSP27 (Ser15 with RatioM/L=3.6, RatioH/M=6.9 
and Ser26 with RatioM/L=5.2, RatioH/M=12). JNKs are well-known stress-activated protein 
kinases and constitute an important branch of MAPK cascades. HSP27 is phosphorylated at 
Ser15, Ser78 and Ser82 by MAPKAP kinase 2 as a result of activation of the p38 MAP kinase 
pathway214. The further up-regulation of JNK pathway and p38 MAPK pathway by U0126 
treatment indicates a potential interplay among several MAPK cascades. As distinctive 
functions of these MAPK family proteins have been reported, attention should be paid to the 
effect of the kinase inhibitors on them.  
Importantly, proteins regulating transcriptional process are found in both datasets with 
RatioH/M>=2 from SB202190 and U0126 experiments. It indicates a long-term effect of the 
inhibitors at the transcriptional and protein expression levels. 
 
4.2.2   Effect of dasatinib on the BCR-ABL signaling pathway 
Chronic myelogenous leukemia (CML) is characterized by over-proliferation of myeloid cells. 
The fundamental principle of its etiology is the fusion of two chromosomes to produce the 
chimeric protein BCR-ABL. In normal physiology Bcr is encoded by chromosome 22 
whereas the non-receptor tyrosine kinase ABL is encoded by chromosome 9. In CML, 
however, the long arms of chromosome 22 and chromosome 9 are fused together, resulting in 
the so-called Philadelphia chromosome and the constitutively activated tyrosine kinase BCR-
ABL215. Two predominant BCR-ABL fusions are involved in CML216: fusion of the first 13 
exons of BCR to exon 2 of ABL results in the b2a2 fusion (e13a2), and fusion of the first 14 
exons of BCR to exon 2 of ABL results in the b3a2 fusion (e14a2).  
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Treatment of CML has been greatly advanced by using small inhibitor compounds to 
selectively inhibit the kinase activity of BCR-ABL. The first BCR-ABL inhibitor drug 
Gleevec®, or imatinib, was rapidly approved by Food and Drug Administration (FDA) in the 
US in the beginning of the 21st century. In fact, the success of imatinib for the first time 
proved the novel concept of using small kinase inhibitor compounds as rational drugs and 
opened a new field in drug development. This achievement was so striking that an editorial 
essay from The Oncologist praised it as breaking the barrier of “The oncologic four-minute 
mile”217. Later, a second generation of inhibitor drugs appeared in the clinic, with the aim of 
inhibiting point-mutated versions of BCR-ABL. Among these is dasatinib (Figure 4.2.7), a 
highly potent, orally active inhibitor for both inactive and active BCR-ABL. Dasatinib is most 
potent towards chronic phase CML, with complete hematologic responses in 90% of patients, 
52% of whom achieved a major hematologic response218. Distinct in chemical structure from 
imatinib, dasatinib is able to inhibit most BCR-ABL variants found in CML patients219. In cell 
line tests, dasatinib displayed an over 300 fold higher potency than imatinib220. Today the 
combination of imatinib and dasatinib is recommended for CML therapy. 
 
 
Figure 4.2.7   Chemical structure of dasatinib. Its chemical name is N-(2-Chloro-6-methyl-
phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-
carboxamide, with the molecular formula: C18H16N6S2. Molecular mass is 380.50 g/mol. 
 
Dasatinib binds to the kinase domains of ABL kinase (Figure 4.2.8). It has a similar potency 
towards Src family kinases and PDGFR221. Research on dasatinib’s mechanism of action 
focuses on two major themes: the direct binding targets and more downstream signaling 
molecules. Mass spectrometry has played an important role in these investigations. Recently 
Goss et al216 analyzed immunoprecipitated protein in tandem MS and derived a common 
phosphotyrosine signature for BCR-ABL in six different CML cell lines. Hantschel et al222 
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and Bantscheff et al201 combined affinity purification technique with quantitative mass 
spectrometry to screen the binding targets of dasatinib. In the study from Bantscheff et al 
seven broad-band inhibitors were immobilized in one affinity column (kinomebead) to test the 
competition of certain kinase inhibitor compounds with those unspecific ligands. Interestingly 
these kinase beads are able to cover 80% of the phylogenetic tree.  
 
 
Figure 4.2.8   Crystal structure of the Abl kinase domain complexed with dasatinib. From 
Hantschel et al.222, based on PDB ID code 2GQG 
 
Here we describe a simplified assay to elucidate the effects of this drug on signaling pathways.  
It employs SILAC-based phosphoproteomics to analyze, for the first time, the effect of a 
current cancer drug in a cell line without any bias and in a systems-wide manner. 
The human immortalized myologeous leukemia cell line K562 bears the e14a2 fusion and 
expresses constitutively activated BCR-ABL. Therefore it serves as a suitable cell model for 
studying CML. In our experiments, three groups of K562 cells were cultured in “light”, 
“medium” and “heavy” SILAC conditions (Figure 4.2.9). In contrast to the MAPK inhibitor 
studies described above no stimulus is necessary because BCR-ABL itself provides a 
constitutive signal. While “light” cells were treated with DMSO only, “medium” and “heavy” 
cells were treated with 5 nM and 50 nM dasatinib for one hour, respectively. In this way, a 
dose dependence can in principle be measured. Cells were harvested and enriched for 
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phosphopeptides as described in section 3.1.5 and 3.3, respectively. Data analysis was 
performed according to section 3.4. The resulting dataset has 99% identification confidence. 
 
 
Figure 4.2.9   Strategy to detect the effect of dasatinib on the cellular signaling network.  
Three populations of SILAC cells were treated with control solution and two different 
inhibitor concentrations for one hour to examine phosphoproteome changes.  
 
4.2.2.1   A large number of phosphosites are suppressed by dasatinib 
We identified 4,833 phosphopeptides from 1,804 proteins, from which 4,286 class I 
phosphosites were derived. About 12% of these phosphopeptides were suppressed by 5 nM 
dasatinib treatment, while a ten-times larger dose of dasatinib down-regulated 16% of the 
phosphopeptides (Table 4.2.2).  As expected, there is much more down-regulation than up-
regulation. Reassuringly, most regulated phosphopeptides and phosphosites in the treatment 
with low dose were also quantified as down-regulated sites in the experiment with high dose 
inhibition (79%). This also implies that these large-scale quantitative phosphorylation 
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experiments were quite reproducible. Interestingly, there was a small proportion of up-
regulated sites as well. However, overlap between these sites is low (~10%). When the 
criterion of down-regulation is loosened to 50% change (Ratio>=1.5), the overlap increases to 
~30% (69 phosphopeptides), with 219 down-regulated phosphopeptides in 5 nM dasatinib 
treatment and 206 in 50 nM dasatinib treatment. These sites will not be discussed further.   
 
Table 4.2.2   Quantitation of phosphopeptides from dasatinib treated K562 cells. 
 Phosphopeptides Class I phosphosites 
All 4833 4286 
Down-
regulation 
(Ratio<=0.5) 
5 nM 587 524 
50 nM 778 708 
overlap 465 424 
Up-regulation 
(Ratio>=2) 
5 nM 52 45 
50 nM 33 29 
overlap 6 3 
 
Dasatinib is known to down-regulate several important signaling proteins. Table 4.2.3 lists 
some of the well-known proteins that were captured in our study. The activating 
autophosphorylation sites of ABL1 (in the fusion protein), SRC, MAPK1 and MAPK3 were 
significantly suppressed, indicating that their kinase activities were reduced. Additionally, 
tyrosine phosphorylation of BCR, LYN and BTK was drastically down-regulated. The pThr-
58 of c-Myc is known to be regulated by mitogen stimulation. It is crucial for various 
functions of c-Myc, such as transcription regulation223, altered intracellular location224, and 
protein degradation225. Following upstream kinase inhibitions, Thr-58 was largely 
dephosphorylated after dasatinib treatment in our experiments. This demonstrates that large-
scale quantitative phosphoproteomics can pin-point crucial sites involved in cell proliferation. 
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Table 4.2.3   Marker phosphopeptides downregulated by dasatinib. 
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4.2.2.2   Proline-directed phosphorylation is dominant in BCR-ABL signaling 
To evaluate the signaling affected by dasatinib, we selected a sequence window of 13 amino 
acids with the down-regulated phosphorylation sites positioned in the center.  The derived 
sequences for those 424 commonly down-regulated phosphorylation sites were submitted to 
WEBLOGO (http://weblogo.berkeley.edu/logo.cgi) for assessing kinase substrate motifs.  
 
 
Figure 4.2.10   WEBLOGO (http://weblogo.berkeley.edu/logo.cgi) evaluates kinase substrate 
motif for the down-regulated phosphorylation sites by both 5 nM and 50 nM dasatinib. The 
frequency plot is depicted here. Upper panel: All 424 down-regulated sites were assessed. 
Lower panel: within the 424 phosphosites, those identified from singly phosphorylated 
peptides were assessed.  
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We submitted all the sequence windows for 424 phosphosites at once (Figure 4.2.10 upper 
panel), as well as selectively submitted those down-regulated sites identified from singly 
phosphorylated peptides (Figure 4.2.10 lower panel).  The resulting frequency plots are very 
similar. Most strikingly, proline-directed phosphorylation (pS/pT-P) accounts for more than 
half of the phosphorylation events. The web logos suggest the substrate motifs of ERK1/2 and 
AKT. To confirm this, we manually filtered the sequence window for the classical ERK1/2 
motif (V/PXpS/pTP) and ATK motif (K/RXRXXpS/pT). Indeed, 91 sequences passed the 
selection for ERK1/2 substrates and 26 for ATK substrates. These numbers indicate ERK1/2 
and AKT signaling cascades make up a significant portion of BCR-ABL signaling pathway. 
 
4.2.2.3   Effect of dasatinib on the overall BCR-ABL signaling pathway 
The accumulating knowledge in BCR-ABL signaling has revealed several critical pathways 
that contribute to chronic myeloid leukemia transformation226. In association with SHC and 
GRB2, BCR-ABL activates ERK1/2 and JAK/STAT pathways and therefore causes cells to 
bypass the growth factor-dependency of proliferation and cell growth. BCR-ABL activates the 
PI3K-AKT and JAK/STAT pathways to enhance cell survival, while its activation of focal 
adhesion components (actin, FAK, CAS, etc) leads to a decrease in cell adhesion and 
abnormal interaction with extra-cellular matrix and stroma.  
According to the summary from Weisberg et al226, we recapitulated the BCR-ABL signaling 
network with details of detected, down-regulated phosphosites (Figure 4.2.11). These 
signaling molecules distribute among the various aforementioned pathways. 
Critical proteins involved in the three major MAPK cascades were suppressed, including the 
autophosphorylation loop of p38α and ERK1/2. This is in agreement with the ERK1/2 kinase 
substrate motif analysis, where a large number of suppressed phosphosites display the 
classical substrate motif for ERK1/2. 
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Figure 4.2.11   Effect of dasatinib on the BCR-ABL signaling pathway. The phosphorylation sites that are suppressed by both 5 nM and 50 nM 
dasatinib are displayed on the left. Signaling pathways are based on Weisberg et al.226.  
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Previous studies provide increasing evidence that a major mechanism of BCR-ABL 
transformation is via suppression of apoptosis227. Primary CML progenitors required growth 
factors for proliferation228. Yet in the absence of serum or growth factors, primary CML 
progenitors had increased cell viability compared to normal cells229. Antisense 
oligonucleotide–mediated down-regulation of BCR-ABL conferred susceptibility of BCR-
ABL positive cells to apoptotic stimuli230 and did not affect cell cycle progression229. We 
captured several sites of the BCL superfamily proteins as well as the p53 binding protein 2, an 
essential regulator of p53 in apoptosis and cell growth. 
Overall, phosphopeptides from 33 phosphatases and 130 kinases were quantified. By applying 
the criterion that at least one phosphorylation has to be suppressed by half, 6 phosphatases and 
27 kinases are selected. Dasatinib is known to bind to a large number of kinases. Carter et al 
tested a panel of 148 kinases and dasatinib influenced 76 of them231. In our dataset – even 
though the selection was broaden to 25% suppression (Ratio<=0.75) – only 14 phosphatases 
and 51 kinases were influenced by dasatinib. This may generally reflect the difference 
between cell line studies and ex vivo enzyme assays. If our observation with dasatinib proves 
to be more widely applicable, it suggests that off target effects from in-vitro effects may not 
be reflected in cells in all cases. One obvious reason for this could be that off-target effects 
depend on the concentration of kinases and substrates. These are usually normalized in-vitro, 
whereas our assay uses the ‘correct’ cellular concentrations. Therefore, if there is an off-target 
effect on a very minor cellular constituent, this may not have an appreciable effect on the 
overall signaling network. Additionally, different cell types retain their cell-type specific 
features to different degrees and therefore may not employ all possible in-vivo substrates to 
respond to a stimulus. Some of the in-vitro targets may not even be expressed in the cell type 
under study.  
These observations indicate that the two major themes, i.e. to study direct binding targets of 
the inhibitor compounds and to investigate their influence on cellular signaling network, 
should be combined. Together we will provide a much more complete picture of the drug 
effects and mechanism of actions. 
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4.2.3   Conclusions and discussions 
In this project we quantified the effects of three kinase inhibitors, including a clinical drug, on 
the phosphorylation changes in the entire cellular signaling network. Two of the inhibitors, 
U0126 and SB202190, are very commonly employed in bench research to elucidate the 
cellular functions of their target kinases. To our knowledge there has been little investigation 
on the overall effects of these inhibitors on the general signaling network and some of the 
derived functions may actually be induced by secondary signaling molecules rather than the 
targeted kinases. Therefore interpretation of the cellular assays must be done with caution.  
We derived a simple EGF signal propagation model based on the suppression of 
phosphorylation by selective MAPK inhibitors, which indicates that MAPK signaling 
cascades are dominant in the early phase of EGF signal transduction, i.e. after 15 minutes of 
150 ng/ml EGF treatment. Bearing in mind that U0126 and SB202190 may not only suppress 
their designed targets (MEK1/2 and p38α/β, respectively), this model is only a rough estimate. 
We applied the same strategy of SILAC-based quantitative phosphoproteomics to inspect the 
cellular effects of dasatinib, a clinical drug for CML therapy. Two different concentrations 
were employed to enhance the reliability of the substrate list. The influenced signaling 
molecules distribute among several critical signaling pathways for BCR-ABL induced CML 
transformation. Specific sites from these signaling molecules were pinpointed, providing site-
specific information of the inhibitory mechanism. 
Phosphorylation is a critical modification for various signal transduction events in normal and 
transformed cells. Selectively inhibiting the crucial kinases or phosphatases has proven a 
useful strategy for correcting the abnormal enzyme activities which can distort cellular 
signaling networks. Establishment of this novel type of drugs in the clinic is represented by 
imatinib, dasatinib, erotinib, and others. As the majority of studies so far have focused on the 
direct binding targets of these inhibitor compounds, there is a need to elucidate their global 
influence on signal transduction. Our quantitative phosphoproteomics approach is able to 
examine the cellular effect at the phosphorylation and - in principle – at the protein expression 
level.  Thus our datasets complement the mechanism of actions previously described for the 
three investigated kinase inhibitors.  
Since the first kinase-targeted inhibitor compound was successfully developed and applied to 
patients, clinicians have been constantly in battle with disease evolution. Besides elevated 
protein expression levels, point mutations have been frequently reported in the targeted 
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kinases. This drug-resistance has motivated scientists to screen more compound libraries and 
further develop inhibitor compounds. To meet the need of testing the efficacy and dynamics 
of the new compounds in an unbiased way and on a global scale, we believe our simple but 
powerful SILAC-based quantitative phosphoproteomics technique can greatly facilitate the 
screening processes from the early phase of the drug development. 
Two interesting concepts have started to emerge in the drug development field: that multi-
kinase inhibitory compounds can be effective drugs and that the combination of multiple 
inhibitors in one therapy can lead to much better clinical results . For example, sunitinib 
exerts antitumor activity and induces tumor regression in cancer patients via inhibition of 
growth promoting signaling in tumor cells (e.g. c-Kit, Flt-3, RET) and of receptors expressed 
on cells of stroma (e.g. VEGFR, PDGFR)75, 232. Combination of pharmacological inhibitors of 
PI3-K (LY294002 and Wortmannin) with imatinib induced more apoptosis in both chronic 
and blast crisis CML cells233. The T315I point mutation in BCR-ABL conferred resistance to 
imatinib and dasatinib. However, a PDK-1 inhibitor (OSU-03012), which essentially inhibits 
Akt activation, can synergize with imatinib in inducing apoptosis even in cells expressing the 
T315I BCR-ABL. As more and more complex inhibitory therapies are attempted, the cellular 
effects of these inhibitor compounds will become even more complicated. With our unbiased, 
high-throughput, and robust technique, we believe that knowledge of principles of drug 
actions can be derived relatively fast and that this can  guide future drug development. 
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4.3 Project 3 - ‘Proteomic phenotyping’ to assess differences between 
transformed and non-transformed mouse liver cells 
 
This work is included in a submitted manuscript:  
 
 
The cell line Hepa1-6 was isolated from the mouse liver with hepatoma170, therefore it is 
thought to retain the characteristics of both mouse hepatocytes and cancer (Section 3.1.1). In 
this project we compared the proteome of freshly isolated hepatocytes from healthy mice and 
the proteome of Hepa1-6, with the aim of characterizing their differences at a systematic and 
quantitative level. Striking differences in protein expression, molecular function and signal 
transduction pathways were revealed. Clearly, cancer-derived cell lines are mostly dedicated 
to proliferation and growth, representing major characteristics of cancer. The primary 
hepatocytes, on the other hand, maintain their functions in metabolism and organ context. 
Proteome quantitation in this study helped to reveal these functional differences at the level of 
the proteome for the first time. This should help to better evaluate research results derived 
from this cell line. More generally, this study alerts the biologists to where cell lines may 
significantly distort intracellular network and therefore where caution should be applied when 
analyzing cell line results. Fortunately, the proteomic phenotyping strategy (Figure 4.3.1) 
presented in this work is very robust. It can be applied to studies like the one presented here, 
i.e. comparing a cell line and their cognate primary cells, but is not limited to this type of 
study. Due to the strength of the novel bioinformatic algorithm (section 3.5.1 and section 
4.3.2) developed in this work, even proteomes originating from distinct sources can be 
compared quantitatively and systematically in terms of specific cellular functions.  
Comparative proteomic phenotyping of cell lines and primary cells to assess 
preservation of cell type specific functions 
Pan, C1; Kumar, C1; Bohl, S; Klingmueller, U; and Mann M. 
1
 both authors contributed equally 
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4.3.1   Proteomes of primary hepatocytes and Hepa1-6 
To characterize phenotypic differences between cell lines and primary cells, we labeled the 
murine hepatoma cell line Hepa1-6 with Arg10 (Arg13C615N4) and Lys8 (Lys13C615N2), i.e. 
heavy forms of the amino acids used in SILAC labeling. Primary hepatocytes were isolated 
from six to twelve weeks old B6 mice according to standard operating procedures established 
by the German systems biology competence network HepatoSys. After isolation primary 
hepatocytes were cultured in dishes for 14 h. Proteins from completely labeled Hepa1-6 and 
primary hepatocytes were extracted and mixed in equal amounts (section 3.1.5). 100 µg of 
proteins from each of two mixtures were separated by isoeletric focusing and analyzed in the 
LTQ-FT using the top 5 LC-MS/MS method (section 3.2). For biological and technical 
replicates, we obtained primary hepatocytes from two mice and treated the samples separately 
during the experiments. Data analysis was done according to section 3.4.1.  
 
 
Figure 4. 3.1   Strategy for comparing primary cells with immortalized cell lines. SILAC 
–labeled Hepa1-6 cell line was combined with mouse primary hepatocytes. After cell lysis 
and digestion peptide mixtures were separated by isoelectric focusing (Offgel) and analyzed 
by LC/MS-MS using an LTQ-FT mass spectrometer. 
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4.3.1.1   Excellent reproducibility of the identification and quantitation of the proteomes 
We used high resolution mass spectrometry to identify and quantify around 4,000 proteins in 
each mixture of primary hepatocytes and Hepa1-6. The overlap of identified proteins is very 
large between the two datasets (Figure 4.3.2, inset). As quantitation in each dataset was 
performed, we also wanted to evaluate if the relative protein expressions were reproducible 
between the biological replicates. With 100% similarity set to be 1, the Pearson correlation 
coefficient of these two datasets is 0.95 (Figure 4.3.2). Given that these two primary 
hepatocyte samples were obtained from different mice, this correlation coefficient is excellent. 
On one hand, this reflects the robustness and stability of our experimental protocols and 
particularly the LC-MS/MS system. On the other hand, the homogenous genetic background 
of these B6 mice also contributed greatly to the reproducibility. 
 
 
Figure 4.3.2   Replicate experiments of comparing Hepa1-6 cell line with primary hepatocytes 
from two mice achieved very high degree of reproducibility at both identification  level 
(inserted in the upper-left corner)  and quantitation level (about 4,000 proteins quantified; 
Person correlation coefficient 0.95).  
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We then combined the two datasets and analyzed them together in MaxQuant using stringent 
and unified criteria (section 3.4.1). At a false positive rate of less than one percent, a total of 
4,089 proteins were identified and quantified between the two cell populations. In the 
following, unless otherwise specified, the analyses were performed on the two proteome 
datasets separately. 
 
4.3.1.2    Drastic changes in protein expressions in primary hepatocytes and Hepa1-6  
We compared the expressions of proteins that were present in both primary hepatocytes and 
Hepa1-6. The primary and cell line proteomes overlap qualitatively but are very different 
quantitatively, with more than half of the proteome changing at least two-fold between the 
two conditions (Figure 4.3.3).  
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Figure 4.3.3   Fold-change distributions of the proteome. (A) Quantitative comparison of the 
Hepa1-6 cell line vs. the primary cell proteome. The distribution was divided into five 
quantiles as follows. High relative expression in primary cells (0-15%, at least four-fold 
down-regulation), mostly expressed in primary cells (15-25%, -4 to -1.5 fold regulation), not 
highly regulated proteins (25-75%;  - 1.5 to +2.8), mostly expressed in Hepa1-6 (75-85; 2.8 to 
3.6 fold), highly expressed in Hepa1-6 (85-100%, more than 3.6 fold change). Color coding of 
these categories is indicated at the top of the panel. (B) Biological replicate of the experiment 
showing excellent reproducibility (see figure 4.3.2). 
 
Many proteins are expressed at much lower levels in the immortalized cell line than in the 
primary cells whereas comparatively few were up-regulated in Hepa1-6. This is surprising 
since cancer cells are thought to be de-differentiated and to express many genes 
inappropriately.  
 
4.3.1.3 Changing glucose level in cell culture does not induce drastic proteome changes  
 
 
Figure 4.3.4   Quantitative comparison of the Hepa1-6 proteome cultured in high glucose (38 
mM) and physiological glucose concentration (8 mM). Two independent comparisons (A) and 
(B) were performed starting from cell culture and SILAC labeling. 
 
It is usually recommended to cultivate Hepa1-6 cells in high glucose medium (38 mM). 
Therefore we asked whether some of the observed phenotypic changes are attributable to this 
circumstance. To address this experimentally, we performed another SILAC experiment 
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comparing Hepa1-6 cells cultured in high glucose against cells cultured in physiological 
glucose levels in mice (8 mM) for three weeks In this experiment, there were hardly any 
overall changes in the proteome and 96% of the proteins were of constant abundance within a 
factor of 1.5 (Figure 4.3.4 A). This was also confirmed in a replicate experiment (Figure 4.3.4 
B). These results rule out a dominant role of the super-physiological glucose level in the 
proteome differences between primary cells and cell lines. Furthermore, they demonstrate 
excellent quantitative accuracy of our experiment on a proteome-wide basis. 
 
4.3.2   Phenotyping of the proteomes of primary hepatocytes and Hepa1-6 
4.3.2.1   Functional clustering on top of quantitative clustering - a method for proteomic 
phenotyping 
To functionally understand the differences between the two cell populations, we divided the 
fold-change distribution between primary hepatocytes and the Hepa1-6 cell line into five 
quantiles according to relative protein expression (Figure 4.3.3). Each quantile was assessed 
separately for overrepresented pathways, biological processes and cellular components with 
Gene Ontology (GO) and KEGG pathway analysis234, 235 (Section 3.5.1). We retained each 
functional category that reached at least 95% statistical significance in one of the quantiles 
and then performed one-way unsupervised clustering of the p-values of the resulting 
categories. This analysis differs from the more familiar clustering of overrepresented genes 
themselves, which is frequently employed in microarray-based experiments. It integrates the 
strength of statistical testing (taking p-values as input for clustering) with the intuitive 
simplicity of hierarchical clustering. By automatically classifying related processes and 
pathways based on their up or down-regulated protein measurements, it provides an unbiased 
global portrait of representative biological functions, enabling visual interpretation of the 
phenotype in terms of aggregate functional modules on a systems level.  
 
4.3.2.2   P-value clustering on the proteomes of primary hepatocytes and Hepa1-6 
We applied this novel p-value clustering strategy to our two proteome datasets. The result of 
KEGG pathway over-representation analysis for one of the dataset is shown in figure 4.3.5 
and Appendix 4. For the same dataset, results from the cellular component category in Gene 
Ontology, and the biological function category in Gene Ontology are displayed in Appendix 5 
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and 6. We verified the robustness of these functional assignments by comparing the shared p-
value matrix of the replicate experiments against each other (Appendix 7-9). This correlation 
was 0.86 for KEGG, 0.85 for GO biological process and 0.92 for GO cellular compartment. 
 
 
Figure 4.3.5   Functional phenotyping of the proteome. The five quantiles (see Figure 4.3.3) 
were separately analyzed for enriched KEGG pathways and clustered for the z-transformed p-
values. The color bar on top represents the quantiles. Representative pathways enriched in the 
protein population of each quantile are annotated. For complete listing of significant 
categories and p-values see Appendix 4.  
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4.3.2.3   Cell growth related proteins are highly expressed in Hepa1-6 
The most prominent cluster of proteins expressed at higher levels in Hepa1-6 relates to cell 
division and encompasses categories such as cell cycle (p < 10-9), DNA synthesis (p < 10-4) 
and RNA polymerase (p < 10-3). This cluster consists of 10 enriched pathways, of which at 
least five relate to increased cell proliferation. Relative expression levels of proteins involved 
in the cell cycle are depicted in Figure 4.3.6. Biologically, this is not surprising since 
hepatocytes in the liver and in our primary culture are largely arrested in the G0 phase of the 
cell cycle, whereas Hepa1-6 cells double every 18 hours. Nevertheless, the fact that this 
phenotypic trait is so clearly grouped in the cluster analysis makes it an excellent positive 
control.  
 
Figure 4.3.6   KEGG pathway mapping of cell cycle. The color bar on top represents the 
quantiles. Proteins that are marked with two colors are likely to represent isoforms. 
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TGFβ-mediated signaling is more highly represented in the Hepa1-6 cell line and the 
canonical members TGFβ R1, Smad2/3, Smad4, p107 and p15 are all up-regulated 
significantly (Figure 4.3.7). This was unexpected because TGFβ  is usually associated with 
growth inhibition whereas Hepa1-6 has increased proliferation rate compared to primary 
hepatocytes. However, the biological actions of TGFβ are complex and it is thought to shift 
from a growth inhibitory to a growth promoting role during cancer development236. Thus up-
regulation of this pathway suggests that in the Hepa1-6 tumor cells, TGFβ may have growth 
promoting effects. Taken together, our data indicate that biological functions related to many 
important signaling pathways are well preserved in Hepa1-6.  
 
 
Figure 4.3.7   Proteomics phenotyping at the pathway level. KEGG pathway mapping shows 
that TGFβ signaling pathway is predominantly present in the cell line. 
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4.3.2.4   Proteins relevant to liver functions are highly expressed in primary hepatocytes 
 
Drug metabolizing enzyme families are highly expressed only in primary cells. 
 One of the most enriched categories in the quantile most expressed in primary cells is the 
P450 family of enzymes (p < 10-16). These enzymes are mainly involved in metabolizing 
endogenous substances and xenobiotics237, a prototypical function of the liver. We identified 
32 different P450 proteins and 25 of them were down-regulated at least tenfold in the cell line. 
Furthermore, the flavin monooxygenase (FMO), UDG-glucuronosyltransferase (UGT), 
sulfotransferase (SULT), and glutathione S-transferase (GST) - additional prominent drug 
metabolizing enzyme families (DMEs) - were also severely down-regulated in Hepa1-6 
(Appendix 10). Only three P450s were up-regulated. Two of them (CYP1A1 and CYP2S1) 
are known to be regulated by the aryl hydrogen receptor238, 239. This receptor was also more 
highly expressed in Hepa1-6, providing a ready explanation for the up-regulation. The third 
up-regulated P450 protein (RIKEN clone E130013F06) has only been characterized on the 
basis of sequence homology and may have functions different from traditional P450 enzymes.  
Reduction of DME activity is a notorious difficulty in toxicological assays in cell lines. 
Toxicologists therefore attempt to stimulate liver cell lines with the aim of boosting DMEs 
activity240. Quantitative knowledge of the changes in the profile of DMEs could provide a 
rational basis to adapt cell systems to more closely mimic hepatocytes in vivo. 
 
Proteins related to liver organ context were highly expressed.  
Another prominent and cell-specific function of hepatocytes is production of plasma proteins. 
Figure 4.3.5 reveals that ‘complement and coagulation cascade’ is specific for the primary 
cells (p < 10-2). Inspection of the pathway involved (Appendix 11) shows that major liver-
produced factors, such as C3, C4, MBP-C, F2, F5, A2M, Serpin A1/C1 and apolipoproteins 
are down-regulated more than five-fold in Hepa1-6 compared to primary hepatocytes. 
Interestingly, p-value clustering in cellular component category revealed a heavy 
overrepresentation of extracellular matrix (p < 10-18) in primary hepatocytes (Appendix 5 and 
8). Apparently, the cell line also shows lower expression of proteins related to communication 
with stroma and with tissue maintenance. Thus, it is likely that loss of tissue context allows 
the cell line to shut down this function, which is nonessential for propagation in culture. 
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Mitochondrial and other metabolic related proteins are highly expressed in primary 
hepatocytes. 
 
In the cellular component p-value clustering, mitochondria are indicated as the most 
overrepresented group in the primary hepatocytes (p < 10-62).  
 
 
 
 
Figure 4.3.8   Phenotypic proteome comparison at the pathway level. Mapping of protein 
ratios on the fatty-acid metabolism pathway reveals that almost the entire module is down-
regulated several-fold in Hepa1-6. Proteins are color-coded according to their relative 
expression in the two cell types according to the scheme in Figure 4.3.3. Proteins that are 
marked with two colors are likely to represent isoforms. 
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It is known that hepatocytes contain 1000–2000 mitochondria per cell making up one fifth of 
the cell volume. Consistent with this feature, we identified a large number of mitochondrial 
proteins. The IPI mouse database used in this study contains 990 proteins with mitochondrial 
annotations. A total of 479 mitochondrial proteins study were found in our proteome, 
comprising around 12% of the proteome. Of these identified mitochondrial proteins, 69% 
were in the asymmetric tail of the distribution, indicating they were expressed several fold 
lower in Hepa1-6 cells than in primary hepatocytes. These proteins carry out well known 
mitochondrial functions, such as fatty acid synthesis, β-oxidation, and alcohol metabolism 
(Figure 4.3.8).  
We independently confirmed this observation by DAPI and Mitotracker staining (Figure 
4.3.9).  
 
Figure 4.3.9   Nuclear (DAPI) and mitochondrial (Mitotracker) staining of primary 
hepatocytes and Hepa1-6 cells. Many primary hepatocytes are binuclear241.  
 
Indeed, primary hepatocyte nuclei were much smaller whereas in these cells mitochondria 
were much more abundant with respect to Hepa1-6. Concurrent with this, fatty acid 
metabolism was drastically down-regulated in Hepa1-6 according to enrichment analysis of 
KEGG pathways (Figure 4.3.5). Likewise, ‘oxidative phosphorylation’ (p < 10-29), ‘urea 
cycle’(p < 10-4) and ‘steroid biosynthesis’ (p < 10-2) were statistically significantly enriched in 
the quantile most expressed in primary hepatocytes. These down-regulated metabolic 
functions at least partially take place in mitochondria. Conversely, parts of the glycolysis 
pathway were up-regulated in Hepa1-6 (Appendix 12). Together, our results portray a drastic 
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metabolic rearrangement, away from oxidative metabolism in the mitochondria and towards 
less efficient anaerobic metabolism. As discussed further below, these findings provide 
evidence for the Warburg hypothesis, that cancer cells shift towards glycolytic metabolic 
pathways242.  
 
4.3.2.5   Proteins involved in several signaling pathways were expressed to similar 
degrees in primary hepatocytes and Hepa1-6 
In the category containing the 50% of proteins with the least change, many household 
functions and organelles including ribosome (p < 10-2), proteasome (p < 10-3), splicing (p < 
10-4) and Golgi apparatus (p < 10-3) are significantly enriched. Interestingly, several signaling 
pathways are also preferentially located in this quantile. These include the ErbB and PI3K 
signaling pathways (Figure 4.3.10). This finding is in agreement with the requirement of 
growth factor containing serum for the maintenance of most cell lines.  
 
 
Figure 4.3.10   Phenotypic proteome comparison at the pathway level. KEGG pathway 
mapping of ErbB and PI3K signaling pathway shows that they are equally present in primary 
cells and the cell line. 
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4.3.2.6   Other observations 
Some categories shared by both cell types and enriched when analyzed using the  KEGG 
database represent  non-liver functions (such as ‘long term potentiation’) or even non-animal 
functions (such as ‘CO2 fixation’).  However, the enzymes found in these categories function 
both in liver tissue as well as in neurons or plants. For example, all identified CO2 fixation 
proteins also function in citric acid cycle. Most identified proteins for long-term potentiation 
are kinases and phosphatases involved in EGF, insulin and other signaling pathways. 
Therefore, overrepresentation of these ‘CO2 fixation’, ‘long term potentiation’ and similar 
categories reflects the still evolving state of annotation of pathway databases rather than a 
limitation of our technology.  
 
4.3.3   Conclusions and discussions 
4.3.3.1    A robust and powerful technique to assess cell type preserved characteristics 
Taking advantage of the ability of SILAC to compare the levels of thousands of proteins in 
different cellular states89, 243 and a novel bioinformatic approach, we have, for the first time, 
compared the proteomes of primary cells to cell lines. The resulting quantitative proteome of 
more than 4,000 proteins had an asymmetric distribution, with many proteins down-regulated 
in the cell line. Bioinformatic analysis of the quantitative proteomics phenotypes revealed that 
Hepa1-6 cells are deficient in mitochondria, reflecting re-arrangement of metabolic pathways, 
drastically up-regulate cell cycle associated functions and largely shut down drug 
metabolizing enzymes characteristic for the liver. This phenotype is ‘rational’ for rapidly 
dividing and not nutrient limited cells and may partly reflect Darwinian selection of cell 
clones.  
Many biological experiments are performed in cell lines since they are readily available and 
readily accessible. The development of tissue culture techniques and establishment of cell 
lines has been ongoing for several decades. However, there are general concerns that cell lines 
may differ from the in vivo situation in important aspects. Cell lines are usually derived from 
tumors and have adapted to growth in culture. Thereby they may lose tissue specific functions 
and acquire a molecular phenotype quite different from cells in vivo. Thus animal experiments 
or studies in primary cell lines are often preferred despite their added complexity. Accurate 
molecular phenotypes to determine if the function to be investigated is preserved in cell lines 
would enable a rational choice of the most appropriate experimental system. In biotechnology 
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and the pharmaceutical industry this goal obtains added urgency in light of efforts to reduce 
animal experimentation to a minimum.  
Here we introduced a straightforward technology to quantify these differences. Our proof-of-
principle study in a mouse liver cell line and their cognate primary cells clearly demonstrated 
drastic functional differences. This quantitative knowledge of proteome changes provides an 
important basis to adapt cell lines to closer resemble physiological conditions. 
Our technology is accurate, relatively rapid and should now allow selection of the appropriate 
cell system based on a global and unbiased profile according to desired biological function. 
Furthermore, it can be used to manipulate the cell line system to better reflect the in vivo 
situation at the proteome level. While we have based our analysis on protein expression levels, 
it could just as well be applied to assess fidelity of signaling pathways in cell lines using 
SILAC-based quantitative and global phosphoproteomics31.  
Our analysis differs in important points from the more familiar measurement of mRNA levels 
by microarray and its associated bioinformatics244. Even though reproducibility of microarray 
chips has become much better during recent years, the data is not quantitative with respect to 
the final, desired parameter – the global change in protein levels. Furthermore, results of any 
specific transcript on the chip generally have to be validated by RT-PCR and then by 
quantitative immunoblotting. This is impractical for large numbers of proteins. In contrast, 
quantitative proteomics inherently contains the fold-change for each protein, and increasingly 
also that of specific isoforms. The quantitative nature of our results also made it possible to 
directly group overrepresented functions and processes instead of the evaluating the 
transcriptional profile. 
Here we have analyzed interesting, but relatively general phenotypic, traits of two cell 
populations. While many of the resulting observations can be immediately rationalized in 
terms of biological function, they have never been quantified in a global and unbiased way. 
The combination of very high quantitative accuracy at the proteome level with increasingly 
accurate pathway databases should allow even richer assessment of the phenotypic state of 
any cell population in the future. Rapid advances in MS techniques and programming 
algorithms have made label-free quantitation more precise and accurate. Thus the algorithms 
described here may also be applicable to more distantly related proteomes and those that 
cannot be SILAC-labeled.  
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4.3.3.2    Molecular basis of metabolic differences between transformed and non-
transformed cells  
Our observation that mitochondrial proteins are drastically under-represented in transformed 
cells is a rediscovery of an old paradigm: the “Warburg effect”. In normal physiology glucose 
oxidation is composed of two steps: glycolysis in the cytoplasm, and the TCA cycle and 
oxidative phosphorylation in mitochondria. However in tumor cells, this principle of 
metabolism is violated. Back in the 1930s, the German biochemist Otto Warburg discovered 
that cancerous cells had elevated glycolysis and produced more lactic acid even in the 
presence of oxygen. This points out that pyruvate, the end product of glycolysis in most 
normal cells, is processed one step further in the cytoplasm to generate lactic acid, while in 
normal physiology it should be transferred to mitochondria. Warburg’s discovery has been 
confirmed by many reports, as reduced mitochondria content and impaired oxidative 
phosphorylation are seen in various cancer types245, 246 and even in slowly growing tumors247. 
Below we speculate that some of the alterations observed in our comparison of transformed 
and non-transformed cells shed light on the molecular basis of the Warburg effect. Note 
however, that it is difficult to separate differences between cancer cells and primary cells from 
differences due to adaption to life in cell culture.  
 
Table 4.3.1   Key proteins involved in TCA cycle and glycolysis distribute differently 
between primary hepatocytes and the transformed hepatocytes Hepa1-6. 
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In our proteome wide comparison study, we quantified key enzymes involved in glucose 
metabolic processes (Table 4.3.1). Two pivotal mitochondrial enzymes in the TCA cycle that 
specifically control ATP production248, fumarate hydratase and succinate dehydrogenase, are 
down-regulated in transformed cells. In contrast, several enzymes involved in glycolysis were 
over-expressed in Hepa1-6, mainly represented by the key proteins involved in rate-limiting 
steps such as hexokinase, phosphofructokinase, and pyruvate kinase. In fact, hexokinase II 
over-expression in hepatoma represented the first significant insight into the molecular basis 
of “Warburg effect”249, 250. It was revealed that hexokinase II directly binds to the 
mitochondrial outer membrane and utilizes mitochondrial ATP to rapidly phosphorylate 
glucose, therefore the first rate-limiting step is overcome and glycolysis is initiated. Tumor 
cells adopt this strategy to ensure a continuous and rapid flux of glycolysis. 
Glycolysis and oxidative phosphorylation are the two major ATP generating pathways within 
cells. While glycolysis alone can generate two ATP molecules, the complete oxidation of 
glucose via glycolysis and oxidative phosphorylation can generate much more - 36 molecules 
ATP. Apparently mitochondria are much more efficient in producing energy. Energy is in 
constant demand for the rapid proliferation of tumor cells. But what are the reasons for tumor 
cells to favor the less efficient energy generating pathway?  
One significant factor is the shrinkage of mitochondria in neoplasm251, 252. We observed that 
over 60% of mitochondrial proteins were under-expressed by at least two-fold in the 
transformed cells (Hepa1-6) compared to non-transformed primary cells. This is in good 
agreement with our fluorescent staining that mitochondria are drastically reduced (Figure 
4.3.9).  
Furthermore, accumulated mutations in mitochondrial DNA (mtDNA) often lead to deficient 
respiration and ATP generation in neoplasm249. One of the causes of mtDNA damage is the 
side product of oxidative phosphorylation, the reactive oxygen species (ROS). ROS damages 
several enzymes involved in the TCA cycle, such as aconitase253. In normal physiology 
reduction of superoxide is carried out by enzymes. Hydrogen peroxide (H2O2) is slowly 
reduced to water by glutathione peroxidase in mitochondria and by peroxisomal enzyme 
catalase in the cytosol249. In our study we observed that the mitochondrial enzyme glutathione 
peroxidase was down-regulated by half in transformed hepatocytes. Therefore it is possible 
that accumulated ROS contributed to the mitochondrial dysfunction and shrinkage in the 
transformed cell line Hepa1-6. As a consequence, the impaired mitochondrial functions may 
contribute to force tumor cells into a switch in the metabolic network.  
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A third significant factor contributing to the metabolic switch is the oxygen deficiency in the 
tumor microenvironment. Rapid proliferation drives tumor cells away from blood vessels, and 
the relatively slow vascularization usually causes a suppressed oxygen supply. As oxygen is 
the ultimate receiver of electrons in oxidative phosphorylation, this hypoxic environment 
hinders execution of this cellular respiration process.   
While the “Warburg effect” reflects the distortion of homeostasis in the whole tumor system, 
it actually represents single cell Darwinian evolution. Tumor cells need to develop an 
alternative strategy to meet the needs of rapid proliferation, growth and survival, and invasion 
to other tissues. The “Warburg effect” can confer a number of benefits to tumor cells. First, it 
provides building blocks for synthesizing biomolecules. The elevated glycolysis and its 
derivative pentose phosphate pathway can generate a large amount of carbon precursors for 
the synthesis of nucleic acids, phospholipids, fatty acids, cholesterol, porphyrins, and so on. 
Second, lactic acid production can regenerate NAD+ from NADH and therefore equilibrate 
the initial conditions for glycolysis. Furthermore it creates an acidic environment where tumor 
cells may be less exposed to attack of the immune system.  
As the “Warburg effect” is apparently very beneficial for tumor development, cells use other 
strategies to promote and strengthen this metabolic switch. Growth factor signaling pathways 
are often reported to be hyper-active in various tumor types. Besides their canonical functions 
of enhancing cell proliferation and survival, some of the RTK signaling proteins also 
influence metabolism. For instance, Ras, PI3K, Akt and BCR-ABL are able to promote 
glycolysis248. In the absence of oxygen, HIF-1 increases the expression of most glycolytic 
enzymes and glucose transporters GLUT1 and GLUT3254. Consistent with these previous 
findings, our study revealed over-expression of several growth factor signaling proteins in 
cancer cells (Table 4.3.2).  
 
Table 4.3.2   Key proteins involved in cancer development and upregulated in Hepa1-6. 
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Enhanced glycolysis is one of the fundamental principles shared by various tumor types. The 
accumulating knowledge of its molecular basis has lead to the development of glycolysis 
inhibitors for cancer therapy248. The strength of this strategy lies in its applicability to all 
tumor cells, which bypasses the difficulty of cancer heterogeneity. Heterogeneity is a 
notorious feature of cancer. Different types of cancer possess multiple genetic and epigenetic 
alterations. Even within the same type of cancer, malignant cell populations may contain 
diverse genetic alterations. This genetic instability can evolve over time, leading to ever 
higher degree of heterogeneity. Therefore target-specific drugs may function only partially in 
clinics. In contrast, a direct attack on the common weakness of all tumor cells, i.e. a heavy 
reliance on glycolysis, may simultaneously suppress various tumor types. As healthy cells can 
consume other energy fuels, such as protein and lipid, glycolysis inhibition may not induce an 
adverse effect in these cells, reducing potential side effects. However, cautions should still be 
exercised as there are indeed organs which employ glucose as a major source of energy. These 
organs include the brain, retina, and testis. For this reason, this inhibition therapy has to be 
adjusted precisely and evaluated thoroughly.  
To date, a few inhibitor compounds targeting glycolysis pathway have been under 
evaluation248. 2-Deoxyglucose, a glucose analog competing as hexokinase substrate, and 
lonidamine which inhibits the kinase activity of hexokinase, have both entered clinical trials. 
Therefore it is likely that in the future, glycolysis inhibition compounds will be applied in 
clinical therapy and contribute to cancer treatment. 
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5 Perspectives 
Even though the current work flow of quantitative mass spectrometry in cell line studies will 
continue to contribute to various topics in cancer research, it is foreseeable that future 
directions will move towards analysis of real clinical samples. Technology innovations will be 
required to fulfill this task. They can come from three major directions: 
 
1. Innovations in proteomics technique 
Clinical samples often come from limited sources. Proteomics technique will have to adjust to 
decreased sample amounts. Currently, in our laboratory a minimum of ten micrograms of 
proteins are required for proteome mapping while for phosphoproteome analysis one 
milligram is generally needed. Therefore there is an urgent need to improve the performance 
of chromatographic separation and mass spectrometry in analyzing low abundance proteins, 
especially in post-translational modifications studies. 
 
2. Innovations in biological research models for proteomics studies 
For convenience and reproducibility, cell line models are regularly used to study cancer. 
However, these ex vivo systems cannot fully represent in vivo conditions. For example, tissue 
context is lost as single cell populations are cultivated in solid plastic dishes. Oxygen 
concentration is significantly increased in cell culture incubators compared to normal 
physiology. As a worse case, hypoxia is a common condition for tumor cell growth, which 
entails further decreased oxygen concentration. Therefore there is a need to improve the 
current models for cancer research. For example, studies on primary cells will become more 
prevalent in the future. Three-dimensional cell culture systems are already frequently used, 
such as Matrigel. Analysis will be more frequently performed on biopsy samples. In this 
regard, protein quantitation can be carried out using the corresponding SILAC labeled cell 
line as an internal standard. In the long run, label-free quantitative mass spectrometry will 
become more robust and may be the method of choice for quantitative proteomics for patient 
samples.  
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3. Innovations in computational biology 
Data mining will become even more important with the advent of more large scale datasets. 
Individual difference should be minimized among patient samples and the significant factors 
contributing to the disease should be highlighted. Integration of various “omics” data will 
certainly improve data mining and reveal valuable biological information at the systems level. 
Mathematical modeling will play an important role, and it may already be widely used in a 
few years from now. 
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Appendix 
Appendix 1   Dendrogram of the human kinome. From Science (New York, N.Y 298, 1912-1934 (2002). 
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Appendix 2   χ2-test to assess enriched kinase motifs in the Hepa1-6 
phosphoproteome from project 1. 
 
  
motif kinase 
class 1 
(observed) 
class 1 
(expected) 
class 1  
(chi-square) 
R.p[ST] PKA 414 236.5 141.21 
R[RK].p[ST] PKA 220 27 1388.57 
KR..p[ST] PKA 82 13.6 345.14 
S..p[ST] CK1 502 357.2 64.19 
[ST]...pS CK1 716 523.8 82.02 
p[ST]..E CK2 772 290.4 858.34 
pS...S GSK3 502 319.7 113.67 
p[ST]P.[RK] CDK2 265 29.5 1893.37 
R..p[ST] CAMK2 817 236.5 1510.35 
R..p[ST]V CAMK2 41 14.3 50.02 
P.p[ST]P ERK 261 16 3765.95 
V.p[ST]P ERK 59 15.6 121.19 
PEp[ST]P ERK 11 1.1 89.12 
R[RST].p[ST].[ST] AKT 134 6.5 2504.87 
R.R..p[ST] AKT 164 13.4 1698 
R..p[ST].R PKC 7 13.4 3.07 
[LVI].[RK]..p[ST] PKD 236 96.9 204.42 
[IEV]pY[EG][EDPN][IVL] LCK 1 0.1 8.11 
[IVL]pY..[PF] ABL 10 1.7 41.35 
[ED]..pY..[DEAGST] SRC 5 3.8 0.4 
pY..[ILVM] ALK 26 18.7 3.68 
[DPSAEN].pY[VLDEINP] EGFR 20 12.8 4.79 
p[ST]P.[KR] CDK1 265 29.5 1893.37 
p[ST]P[KR] CDK1 166 29.5 636.09 
[RK].p[ST][ILV] Aurora 133 96.9 13.77 
[RKN]R.p[ST][MILV] Aurora-A 61 8 351.8 
[DE].p[ST][VILM].[DE] PLK 13 12.9 0 
[ED].p[ST][FLIYWVM] PLK1 73 147.1 38.69 
L..p[ST] NEK6 272 412.8 53.29 
L.R..p[ST] CHK1/2 108 23.4 307.58 
[MILV].[RK]..p[ST] CHK1 260 107.4 222.54 
F..Fp[ST][FY] PDK1 2 0.4 6.4 
[FLM][RK][RK]p[ST] NIMA 13 8.6 2.26 
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Appendix 3 A   Motif extraction for serine phosphorylation (Hepa1-6 
phosphoproteome from project 1) by Motif-X algorithm.  
Motif Motif Score Foreground Matches Foreground Size Fold Increase 
R-X-X-pS-P-X-P 37.77 40 3653 20.02 
pS-P-X-K 31.95 116 3613 10.27 
K-X-X-X-X-P-X-pS-P 37.35 22 3497 23.48 
P-X-pS-P 27.79 182 3475 7.14 
R-X-X-pS-P 27.51 98 3293 8.63 
pS-P-X-R 26.40 85 3195 8.39 
pS-D-X-E-X-E 41.56 67 3110 37.98 
pS-P-X-X-X-X-K 24.58 65 3043 8.44 
R-X-R-X-X-pS-X-S 36.55 41 2978 14.04 
D-pS-E-X-E 44.40 49 2937 29.84 
K-X-X-X-X-X-pS-P 23.51 55 2888 8.41 
R-R-X-pS 32.00 115 2833 8.96 
D-X-pS-D-X-E 38.53 35 2718 40.63 
R-X-X-X-pS-P 20.95 51 2683 7.17 
pS-D-X-E-D 39.39 32 2632 40.83 
E-pS-E-X-E 39.08 33 2600 22.81 
G-X-X-pS-P 20.90 62 2567 6.56 
R-S-X-pS-X-X-X-L 35.09 25 2505 17.89 
G-X-X-pS-P 20.90 62 2567 6.56 
pS-D-X-E 32.00 98 2480 12.39 
L-X-R-S-X-pS 29.68 23 2382 16.59 
K-X-X-pS-P 20.44 38 2359 7.67 
R-X-R-X-X-pS 25.76 67 2321 7.76 
R-X-X-pS-X-S 32.00 79 2254 6.63 
pS-P 16.00 362 2175 3.85 
D-pS-D-X-D 43.13 38 1813 50.56 
E-X-X-pS-E-X-E 37.47 23 1775 26.10 
pS-X-E-D 32.00 74 1752 9.30 
pS-X-D-E 32.00 53 1678 10.71 
R-X-X-pS-X-D 22.75 32 1625 9.44 
pS-X-X-E-X-E 26.65 51 1593 6.12 
pS-X-X-S-X-X-E 28.09 54 1542 4.92 
R-K-X-pS 23.75 36 1488 9.05 
pS-D-X-D 28.72 43 1452 10.75 
pS-X-E-E 26.85 49 1409 5.75 
K-R-X-pS 32.00 45 1360 10.42 
R-X-X-pS-X-P 21.63 32 1315 7.53 
pS-E-X-D 24.12 32 1283 8.30 
R-R-pS 25.61 33 1251 7.64 
R-X-X-pS 16.00 125 1218 2.87 
D-pS-X-D 25.39 27 1093 9.95 
R-X-X-S-X-X-pS 27.19 43 1066 5.80 
R-pS-X-S 24.92 35 1023 5.93 
pS-X-X-X-E-D 21.84 29 988 7.05 
pS-X-X-E-D 21.68 25 959 8.18 
D-S-X-pS 18.25 24 934 5.09 
pS-L-D 15.89 20 910 4.93 
pS-X-S-D 16.18 24 890 6.22 
G-pS 10.78 118 866 1.91 
pS-S-P 15.20 32 748 4.49 
K-pS 9.72 77 716 2.19 
S-X-X-pS 8.46 119 639 1.72 
pS-X-X-X-X-X-D 9.63 58 520 2.51 
pS-X-D 6.80 42 462 2.44 
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E-pS 7.32 53 420 2.24 
pS-L 5.34 71 367 1.71 
S-X-pS 4.64 52 296 1.80 
pS-X-X-X-X-P 4.93 35 244 2.19 
pS-X-S 4.44 39 209 1.96 
R-pS 4.87 24 170 2.65 
R-X-pS 4.18 20 146 2.66 
 
 
Appendix 3 B    Motif extraction for threonine phosphorylation (Hepa1-6 phospho-
proteome from project 1) by Motif-X algorithm. 
Motif Motif Score Foreground Matches Foreground Size Fold Increase 
pT-P-P 22.24 33 427 14.18 
P-X-pT-P 20.67 29 394 11.72 
pT-P 16.00 95 365 4.75 
pT-X-X-E 10.70 50 270 2.86 
pT-X-P 8.03 38 220 2.80 
pT-X-X-D 9.66 33 182 3.57 
R-X-X-pT 5.65 24 149 2.93 
S-X-pT 4.91 27 125 2.43 
 
 
 
  
Appendix 
139 
 
Appendix 4      Primary hepatocyte vs. Hepa1-6 cell line Sample 1 enriched KEGG 
pathway categories clustered. Five quantiles according to Figure 4.3.3 were accessed.  
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Appendix 5   Primary hepatocyte vs. Hepa1-6 cell line Sample 1 enriched GO 
cellular component categories clustered. Five quantiles according to Figure 4.3.3 were 
accessed. 
Appendix 
141 
 
Appendix 6   Primary hepatocyte vs. Hepa1-6 cell line Sample 1 enriched GO 
biological processes categories clustered. Five quantiles according to Figure 4.3.3 
were accessed. 
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Enlarged Appendix 6 
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Appendix 7      Primary hepatocyte vs. Hepa1-6 cell line Sample 2 enriched KEGG 
pathway categories clustered. Five quantiles according to Figure 4.3.3 were accessed. 
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Appendix 8   Primary hepatocyte vs. Hepa1-6 cell line Sample 2 enriched GO 
cellular component categories clustered. Five quantiles according to Figure 4.3.3 were 
accessed.
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Appendix 9   Primary hepatocyte vs. Hepa1-6 cell line Sample 2 enriched GO 
biological processes categories clustered. Five quantiles according to Figure 4.3.3 
were accessed. 
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Enlarged Appendix 9 
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Appendix 10    Protein ratios for drug metabolizing enzymes in proteome comparison of primary hepatocyte vs. Hepa1-6 cell line 
(project 3). 
 
Family Protein Names Uniprot ID Number of  
peptides 
Number of 
unique peptides 
Ratio H/L 
Normalized 
Ratio H/L 
Count 
Cytochrome P450s 
CYP 1A2 P00186 9 5 0.07 3 
CYP 27 Q9DBG1 13 13 0.02 23 
CYP 2A12 P56593 24 21 0.04 29 
CYP 2A4 P15392 5 1 0.07 4 
CYP 2B19 O55071 6 1 0.01 3 
CYP 2B20 Q62397 16 11 0.09 17 
CYP 2C29 Q64458 11 6 0.04 12 
CYP 2C37 P56654 9 1 0.05 4 
CYP 2C40 P56657 6 6 0.03 10 
CYP 2C44 Q3UEM4 3 3 0.14 2 
CYP 2C54 Q6XVG2 9 2 0.01 1 
CYP 2C70 Q91W64 17 17 0.07 9 
CYP 2D10 P24456 12 4 0.02 16 
CYP 2D26 Q8CIM7 16 12 0.02 22 
CYP 2D9 P11714 10 6 0.02 7 
CYP 2E1 Q05421 10 10 0.03 7 
CYP 2F2 P33267 22 22 0.03 31 
CYP 2J5 O54749 3 3 0.03 3 
CYP 39A1 Q9JKJ9 3 3 0.07 3 
CYP 3A11 Q64459 4 4 0.04 3 
CYP 3A13 Q64464 6 6 0.06 12 
CYP 4A12 Q91WL5 11 11 0.07 8 
CYP 4F13 Q99KY6 2 2 0.18 2 
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CYP 4F14 Q9EP75 2 2 0.02 2 
CYP 4V3 Q9DBW0 6 6 0.03 7 
CYP 7B1 Q60991 10 10 0.07 15 
CYP, 2D22 Q91W87 9 5 0.02 5 
CYP, family 51 Q8BSQ7 4 4 0.11 3 
NADPH--CYP reductase P37040 17 17 0.44 50 
CYP 2S1 Q9DBX6 7 7 6.54 12 
CYP 1A1 P00184 10 6 0.79 21 
RIKEN clone: E130013F06 Q80Y48 4 4 1.92 8 
 
Flavin monooxygenase Flavin containing 
monooxygenase 5 
P97872 8 8 0.028 10 
 
UDP-
glucuronosyltransferase 
UGT 1-9 Q62452 6 3 0.028 5 
UGT 1-6 Q64435 12 3 0.02 16 
UGT 1-1 Q63886 10 7 0.031 16 
UGT 2B5 P17717 11 2 0.067 15 
RIKEN clone:C730026L17, 
similar to UGT 2B5 
Q3UEI8 8 5 0.01 2 
RIKEN clone:C730009A09, 
UGT 2 family 
Q3UEC9 12 8 0.014 14 
 
Sulfotransferase 
Arylsulfotransferase ST1A4 P52840 10 10 0.019 24 
Estrogen sulfotransferase, 
testis isoform 
P49891 2 2 0.04 1 
Sulfotransferase family 
cytosolic 1B member 1, 
Q9QWG7-1 4 4 0.167 2 
Tyrosine-ester 
sulfotransferase 
O35401 7 7 0.024 12 
RIKEN clone:A530080C09 Q8BGL3 11 11 0.017 19 
Heparan sulfate 2-O-
sulfotransferase 1 
Q8R3H7 1 1 1.788 1 
 
glutathione S-
transferase 
GST A2, A1, alpha 1, alpha 2 P10648;P13745; 6 3 0.034 4 
GST alpha 1, alpha 2 Q6P8Q0;Q6P8Q1; 6 3 0.034 4 
GST A3 P30115 10 7 0.008 50 
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GST A4 P24472 5 4 0.025 8 
GST kappa 1 Q9DCM2 14 14 0.016 29 
GST Mu 1 P10649 20 13 0.046 134 
GST Mu 2 P15626 15 8 0.47 40 
GST Mu 3 P19639 12 5 0.054 9 
GST P 1;GST P 2; P19157;P46425 15 14 0.033 196 
GST A3 P30115 10 7 0.008 50 
GST A4 P24472 5 4 0.025 8 
GST kappa 1 Q9DCM2 14 14 0.016 29 
GST Mu 1 P10649 20 13 0.046 134 
GST Mu 2 P15626 15 8 0.47 40 
GST Mu 3 P19639 12 5 0.054 9 
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Appendix 11   KEGG pathway mapping of "complement and coagulation pathways" for 
proteome comparison of primary hepatocyte vs. Hepa1-6 cell line (project 3). 
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Appendix 12   KEGG pathway mapping of "glycolysis" for proteome comparison of primary 
hepatocyte vs. Hepa1-6 cell line (project 3). 
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